US20060278243A1 - Methods of treating inflammation in airways - Google Patents

Methods of treating inflammation in airways Download PDF

Info

Publication number
US20060278243A1
US20060278243A1 US11/421,444 US42144406A US2006278243A1 US 20060278243 A1 US20060278243 A1 US 20060278243A1 US 42144406 A US42144406 A US 42144406A US 2006278243 A1 US2006278243 A1 US 2006278243A1
Authority
US
United States
Prior art keywords
airway
lung
treatment
energy
energy transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US11/421,444
Other versions
US8534291B2 (en
Inventor
Christopher Danek
Michael Biggs
Bryan Loomas
Michael Laufer
Gary Kaplan
Kelly Shriner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Scientific Scimed Inc
Original Assignee
Asthmatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/296,040 external-priority patent/US6411852B1/en
Priority claimed from US09/349,715 external-priority patent/US6488673B1/en
Priority claimed from US09/436,455 external-priority patent/US7425212B1/en
Priority to US11/421,444 priority Critical patent/US8534291B2/en
Application filed by Asthmatx Inc filed Critical Asthmatx Inc
Publication of US20060278243A1 publication Critical patent/US20060278243A1/en
Assigned to ASTHMATX, INC. reassignment ASTHMATX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRONCUS TECHNOLOGIES, INC., BIGGS, MICHAEL, DANEK, CHRISTOPHER JAMES, LOOMAS, BRYAN, SHRINER, KELLY, KAPLAN, GARY, LAUFER, MICHAEL D.
Assigned to BRONCUS TECHNOLOGIES, INC. reassignment BRONCUS TECHNOLOGIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIGGS, MICHAEL, DANEK, CHRISTOPHER JAMES, LOOMAS, BRYAN, SHRINER, KELLY, KAPLAN, GARY, LAUFER, MICHAEL D.
Assigned to ASTHMATX, INC. reassignment ASTHMATX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRONCUS TECHNOLOGIES, INC.
Priority to US13/852,067 priority patent/US8733367B2/en
Publication of US8534291B2 publication Critical patent/US8534291B2/en
Application granted granted Critical
Assigned to BOSTON SCIENTIFIC SCIMED, INC. reassignment BOSTON SCIENTIFIC SCIMED, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASTHMATX, INC.
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/08Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by means of electrically-heated probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B18/1485Probes or electrodes therefor having a short rigid shaft for accessing the inner body through natural openings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B18/1492Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0043Catheters; Hollow probes characterised by structural features
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M29/00Dilators with or without means for introducing media, e.g. remedies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0601Apparatus for use inside the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/22004Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00017Electrical control of surgical instruments
    • A61B2017/00115Electrical control of surgical instruments with audible or visual output
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00292Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery mounted on or guided by flexible, e.g. catheter-like, means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00292Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery mounted on or guided by flexible, e.g. catheter-like, means
    • A61B2017/003Steerable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22051Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation
    • A61B2017/22062Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation to be filled with liquid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053Mechanical features of the instrument of device
    • A61B2018/00059Material properties
    • A61B2018/00071Electrical conductivity
    • A61B2018/00083Electrical conductivity low, i.e. electrically insulating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053Mechanical features of the instrument of device
    • A61B2018/00214Expandable means emitting energy, e.g. by elements carried thereon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053Mechanical features of the instrument of device
    • A61B2018/00214Expandable means emitting energy, e.g. by elements carried thereon
    • A61B2018/0022Balloons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053Mechanical features of the instrument of device
    • A61B2018/00214Expandable means emitting energy, e.g. by elements carried thereon
    • A61B2018/00267Expandable means emitting energy, e.g. by elements carried thereon having a basket shaped structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00541Lung or bronchi
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00642Sensing and controlling the application of energy with feedback, i.e. closed loop control
    • A61B2018/00654Sensing and controlling the application of energy with feedback, i.e. closed loop control with individual control of each of a plurality of energy emitting elements
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00666Sensing and controlling the application of energy using a threshold value
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00666Sensing and controlling the application of energy using a threshold value
    • A61B2018/00678Sensing and controlling the application of energy using a threshold value upper
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00696Controlled or regulated parameters
    • A61B2018/00761Duration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00791Temperature
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00791Temperature
    • A61B2018/00797Temperature measured by multiple temperature sensors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00791Temperature
    • A61B2018/00803Temperature with temperature prediction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B2018/044Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating the surgical action being effected by a circulating hot fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B2018/044Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating the surgical action being effected by a circulating hot fluid
    • A61B2018/046Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating the surgical action being effected by a circulating hot fluid in liquid form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B2018/1807Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using light other than laser radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/36Image-producing devices or illumination devices not otherwise provided for
    • A61B90/361Image-producing devices, e.g. surgical cameras
    • A61B2090/3614Image-producing devices, e.g. surgical cameras using optical fibre
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0067Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0082Catheter tip comprising a tool
    • A61M2025/0096Catheter tip comprising a tool being laterally outward extensions or tools, e.g. hooks or fibres
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00Anatomical parts of the body
    • A61M2210/10Trunk
    • A61M2210/1025Respiratory system
    • A61M2210/1039Lungs

Definitions

  • the invention relates to a method of treating a lung having at least one symptom of reversible obstructive pulmonary disease, and more particularly, the invention relates to advancing a treatment device into the lung and treating the lung with the device to at least reduce the ability of the lung to produce at least one of the symptoms of reversible obstructive pulmonary disease.
  • the invention includes additional steps that reduce the ability of the lung to produce at least one of the symptoms of reversible obstructive pulmonary disease and to reduce the resistance to the flow of air through a lung.
  • Reversible obstructive pulmonary disease includes asthma and reversible aspects of chronic obstructive pulmonary disease (COPD).
  • Asthma is a disease in which (i) bronchoconstriction, (ii) excessive mucus production, and (iii) inflammation and swelling of airways occur, causing widespread but variable airflow obstruction thereby making it difficult for the asthma sufferer to breathe.
  • Asthma is a chronic disorder, primarily characterized by persistent airway inflammation. However, asthma is further characterized by acute episodes of additional airway narrowing via contraction of hyper-responsive airway smooth muscle.
  • the reversible aspects of COPD generally describe excessive mucus production in the bronchial tree. Usually, there is a general increase in bulk (hypertrophy) of the large bronchi and chronic inflammatory changes in the small airways. Excessive amounts of mucus are found in the airways and semisolid plugs of mucus may occlude some small bronchi. Also, the small airways are narrowed and show inflammatory changes.
  • the reversible aspects of COPD include partial airway occlusion by excess secretions, and airway narrowing secondary to smooth muscle contraction, bronchial wall edema and inflation of the airways
  • asthma can also lead to remodeling of the airway wall (i.e., structural changes such as thickening or edema) which can further affect the function of the airway wall and influence airway hyper-responsiveness.
  • Other physiologic changes associated with asthma include excess mucus production, and if the asthma is severe, mucus plugging, as well as ongoing epithelial denudation and repair.
  • Epithelial denudation exposes the underlying tissue to substances that would not normally come in contact with them, further reinforcing the cycle of cellular damage and inflammatory response.
  • asthma symptoms include recurrent episodes of shortness of breath (dyspnea), wheezing, chest tightness, and cough.
  • dyspnea shortness of breath
  • wheezing wheezing
  • chest tightness chest tightness
  • cough Currently, asthma is managed by a combination of stimulus avoidance and pharmacology.
  • Stimulus avoidance is accomplished via systematic identification and minimization of contact with each type of stimuli. It may, however, be impractical and not always helpful to avoid all potential stimuli.
  • Asthma is managed pharmacologically by: (1) long term control through use of anti-inflammatories and long-acting bronchodilators and (2) short term management of acute exacerbations through use of short-acting bronchodilators. Both of these approaches require repeated and regular use of the prescribed drugs. High doses of corticosteroid anti-inflammatory drugs can have serious side effects that require careful management. In addition, some patients are resistant to steroid treatment. The difficulty involved in patient compliance with pharmacologic management and the difficulty of avoiding stimulus that triggers asthma are common barriers to successful asthma management.
  • the present invention relates to methods for treating a lung, preferably having at least one symptom of reversible obstructive pulmonary disease, comprising the steps of advancing a treatment device into the lung and treating the lung with the device to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease and to decrease the resistance to the flow of air through the lung.
  • a variation of the invention includes the method described above further comprising the step of locating one or more treatment sites within an airway of the lung, selecting at least one of the treatment sites and treating at least one of the treatment sites selected in the selecting step.
  • the invention may further include performing the steps while the lung is experiencing at least one symptom of either natural or artificially induced reversible obstructive pulmonary disease.
  • a further variation of the invention includes the method described above and further includes the steps of testing the lung for at least one pre-treatment pulmonary function value prior to the treating step, and re-testing the lung for at least one post-treatment pulmonary function value subsequent to the treating step.
  • Another variation of the invention includes the method described above where treating at least airway tissue at a treatment site within the lung further comprises the step of monitoring electrical impedance of tissue at one or more points.
  • Another variation of the invention includes the method described above where the treating step includes treating the lung by depositing a radioactive substance in at least one treatment site within the lung.
  • Another variation of the invention include the method described above further including the step of scraping tissue from a wall of an airway within the lung prior to the treating step.
  • the invention may further comprise depositing a substance on the scraped wall of the airway.
  • Another variation of the invention includes the method described above where the treating step uses a modality selected from the group consisting of mechanical, chemical, radio frequency, radioactive energy, heat, and ultrasound.
  • Another variation of the invention includes the method described above further comprising pre-treating the lung to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease prior to the treating step, where at least one parameter of the pre-treating step is lesser than at least one parameter of the treating step.
  • Another variation of the invention comprises the method described above where the treating step includes separating the treating step into stages to reduce the healing load on the lung.
  • the separating step may comprise treating different regions of the lung at different times or dividing the number of treatment sites into a plurality of groups of treatment sites and treating each group at a different time.
  • Another variation of the invention includes the method described above further comprising sensing movement of the lung and repositioning the treatment device in response to said sensing step.
  • Another variation of the invention includes the method described above further comprising reducing the temperature of lung tissue adjacent to a treatment site.
  • Another variation of the invention includes the method described above further comprising the step of providing drug therapy, exercise therapy, respiratory therapy, and/or education on disease management techniques to further reduce the effects of reversible obstructive pulmonary disease.
  • the invention further includes the method for reversing a treatment to reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease comprising the step of stimulating re-growth of smooth muscle tissue in the lung.
  • the invention further includes the method of evaluating an individual having reversible obstructive pulmonary disease as a candidate for a procedure to reduce the ability of the individual's lung to produce at least one reversible obstructive pulmonary disease symptom by treating an airway within the lung of the individual, the method comprising the steps of assessing the pulmonary condition of the individual, comparing the pulmonary condition to a corresponding predetermined state; and evaluating the individual based upon the comparing step.
  • the method may additionally comprise the steps of performing pulmonary function tests on the individual to obtain at least one pulmonary function value, comparing the at least one pulmonary function value to a corresponding predetermined pulmonary function value, and evaluating the individual based upon the comparing step.
  • the invention further comprises a method of evaluating the effectiveness of a procedure to reduce the ability of lung to produce at least one symptom of reversible obstructive pulmonary disease previously performed on an individual having reversible obstructive pulmonary disease, the method comprising the steps of assessing the pulmonary condition of the individual, comparing the pulmonary condition to a corresponding predetermined state; and evaluating the effectiveness of the procedure based upon the comparing step.
  • the method may additionally comprise the steps of performing pulmonary function tests on the individual to obtain at least one pulmonary function value, treating the lung to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease, performing post-procedure pulmonary function tests on the individual to obtain at least one post-procedure pulmonary function value; and comparing the pulmonary function value with the post-procedure pulmonary function value to determine the effect of the treating step.
  • FIG. 1 is a cross sectional view of an airway in a healthy lung.
  • FIG. 3 illustrates the airway of FIG. 1 in which the smooth muscle 14 has hypertrophied and increased in thickness causing reduction of the airway diameter.
  • FIG. 4 is a schematic side view of the lungs being treated with a treatment device 38 as described herein.
  • the invention relates to methods for improving airflow through the airways of a lung having reversible obstructive pulmonary disease. It is intended that the invention is applicable to any aspect of reversible obstructive pulmonary disease, including but not limited to asthma.
  • One way of improving airflow is to decrease the resistance to airflow within the lungs. There are several approaches to reducing this resistance, including but not limited to reducing the ability of the airway to contract, increasing the airway diameter, reducing the inflammation of airway tissues, and/or reducing the amount of mucus plugging of the airway.
  • the present invention includes advancing a treatment device into the lung and treating the lung to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease.
  • the inventive treatment reduces the ability of the airways to narrow or to reduce in diameter due to airway smooth muscle contraction.
  • the inventive treatment uses a modality of treatments including, but not limited to the following: chemical, radio frequency, radioactivity, heat, ultrasound, radiant, laser, microwave, or mechanical energy (such as in the form of cutting, punching, abrading, rubbing, or dilating).
  • This treatment reduces the ability of the smooth muscle to contract thereby lessening the severity of an asthma attack.
  • the reduction in the ability of the smooth muscle to contract may be achieved by treating the smooth muscle itself or by treating other tissues which in turn influence smooth muscle contraction or the response of the airway to the smooth muscle contraction. Treatment may also reduce airway responsiveness or the tendency of the airway to narrow or to constrict in response to a stimulus.
  • the amount of smooth muscle surrounding the airway can be reduced by exposing the smooth muscle to energy which either kills the muscle cells or prevents these cells from replicating.
  • the reduction in smooth muscle reduces the ability of the smooth muscle to contract and to narrow the airway during a spasm.
  • the reduction in smooth muscle and surrounding tissue has the added potential benefit of increasing the caliber or diameter of the airways, this benefit reduces the resistance to airflow through the airways.
  • the device used in the present invention may also eliminate smooth muscle altogether by damaging or destroying the muscle.
  • the elimination of the smooth muscle prevents the contraction or spasms of hyper-reactive airways of a patient having reversible obstructive pulmonary disease. By doing so, the elimination of the smooth muscle may reduce some symptoms of reversible obstructive pulmonary disease.
  • the ability of the airway to contract can also be altered by treatment of the smooth muscle in particular patterns.
  • the smooth muscle is arranged around the airways in a generally helical pattern with pitch angles ranging from about ⁇ 38 to about +38 degrees.
  • the treatment of the smooth muscle in appropriate patterns interrupts or cuts through the helical pattern of the smooth muscle at a proper pitch and prevents the airway from constricting.
  • This procedure of patterned treatment application eliminates contraction of the airways without completely eradicating smooth muscle and other airway tissue.
  • a pattern for treatment may be chosen from a variety of patterns including longitudinal or axial stripes, circumferential bands, helical stripes, and the like as well as spot patterns having rectangular, elliptical, circular or other shapes. The size, number, and spacing of the treatment bands, stripes, or spots are chosen to provide a desired clinical effect of reduced airway responsiveness while limiting insult to the airway to a clinically acceptable level.
  • the patterned treatment of the tissues surrounding the airways with energy provides various advantages.
  • the careful selection of the portion of the airway to be treated allows desired results to be achieved while reducing the total healing load.
  • Patterned treatment can also achieve desired results with decreased morbidity, preservation of epithelium, and preservation of a continuous or near continuous ciliated inner surface of the airway for mucociliary clearance.
  • the pattern of treatment may also be chosen to achieve desired results while limiting total treatment area and/or the number of airways treated, thereby improving speed and ease of treatment.
  • Application of energy to the tissue surrounding the airways may also cause the DNA of the cells to become cross linked.
  • the treated cells with cross linked DNA are incapable of replicating. Accordingly, over time, as the smooth muscle cells die, the total thickness of smooth muscle decreases because of the inability of the cells to replicate.
  • the programmed cell death causing a reduction in the volume of tissue is called apoptosis.
  • This treatment does not cause an immediate effect but causes shrinking of the smooth muscle and opening of the airway over time and substantially prevents re-growth.
  • the application of energy to the walls of the airway may also be used to cause a cross linking of the DNA of the mucus gland cells thereby preventing them from replicating and reducing excess mucus plugging or production over time.
  • the ability of the airways to contract may also be reduced by altering mechanical properties of the airway wall, such as by increasing stiffness of the wall or by increasing parenchymal tethering of the airway wall. Both of these methods increase the strength of the airway wall and further oppose contraction and narrowing of the airway.
  • One way to increase stiffness is to induce fibrosis or a wound healing response by causing trauma to the airway wall.
  • the trauma can be caused by delivery of therapeutic energy to the tissue in the airway wall, by mechanical insult to the tissue, or by chemically affecting the tissue.
  • the energy is preferably delivered in such a way that it minimizes or limits the intra-luminal thickening that may occur.
  • the mucosal layer includes the epithelium, its basement membrane, and the lamina basement, a subepithelial collagen layer.
  • the submucosal layer may also play a role in airway folding. As an airway narrows, its perimeter remains relatively constant, with the mucosal layer folding upon itself. As the airway narrows further, the mucosal folds mechanically interfere with each other, effectively stiffening the airway. In asthmatic patients, the number of folds is fewer and the size of the folds is larger, and thus, the airway is free to narrow with less mechanical interference of mucosal folds than in a healthy patient. Thus, asthmatic patients have a decrease in airway stiffness and the airways have less resistance to narrowing.
  • the mucosal folding can also be increased by encouraging a greater number of smaller folds by reducing the thickness of the mucosa and/or submucosal layer.
  • the decreased thickness of the mucosa or submucosa may be achieved by application of energy which either reduces the number of cells in the mucosa or submucosal layer or which prevents replication of the cells in the mucosa or submucosal layer.
  • a thinner mucosa or submucosal layer will have an increased tendency to fold and increased mechanical stiffening caused by the folds.
  • the parenchyma surrounds airways and includes the alveolus and tissue connected to and surrounding the outer portion of the airway wall.
  • the parenchyma includes the alveolus and tissue connected to and surrounding the cartilage that supports the larger airways.
  • the parenchyma provides a tissue network which connects to and helps to support the airway. Edema or accumulation of fluid in lung tissue in patients with asthma or COPD is believed to decouple the airway from the parenchyma reducing the restraining force of the parenchyma which opposes airway constriction. Energy can be used to treat the parenchyma to reduce edema and/or improve parenchymal tethering.
  • the applied energy may be used to improve connection between the airway smooth muscle and submucosal layer to the surrounding cartilage, and to encourage wound healing, collagen deposition, and/or fibrosis in the tissue surrounding the airway to help support the airway and prevent airway contraction.
  • Hypertrophy of smooth muscle, chronic inflammation of airway tissues, and general thickening of all parts of the airway wall can reduce the airway diameter in patients with reversible obstructive pulmonary disease.
  • Increasing the overall airway diameter using a variety of techniques can improve the passage of air through the airways.
  • Application of energy to the airway smooth muscle of an asthmatic patient can debulk or reduce the volume of smooth muscle. This reduced volume of smooth muscle increases the airway diameter for improved air exchange.
  • Reducing inflammation and edema of the tissue surrounding the airway can also increase the diameter of an airway.
  • Inflammation and edema (accumulation of fluid) of the airway are chronic features of asthma.
  • the inflammation and edema can be reduced by application of energy to stimulate wound healing and regenerate normal tissue.
  • Healing of the epithelium or sections of the epithelium experiencing ongoing denudation and renewal allows regeneration of healthy epithelium with less associated airway inflammation.
  • the less inflamed airway has an increased airway diameter both at a resting state and in constriction.
  • the wound healing can also deposit collagen which improves parenchymal tethering.
  • Inflammatory mediators released by tissue in the airway wall may serve as a stimulus for airway smooth muscle contraction.
  • Therapy that reduces the production and release of inflammatory mediator can reduce smooth muscle contraction, inflammation of the airways, and edema.
  • inflammatory mediators are cytokines, chemokines, and histamine.
  • the tissues which produce and release inflammatory mediators include airway smooth muscle, epithelium, and mast cells. Treatment of these structures with energy can reduce the ability of the airway structures to produce or release inflammatory mediators. The reduction in released inflammatory mediators will reduce chronic inflammation, thereby increasing the airway inner diameter, and may also reduce hyper-responsiveness of the airway smooth muscle.
  • a further process for increasing the airway diameter is by denervation.
  • a resting tone of smooth muscle is nerve regulated by release of catecholamines.
  • the resting tone of the smooth muscle is reduced, and the airway diameter is increased. Resting tone may also be reduced by directly affecting the ability of smooth muscle tissue to contract.
  • Excess mucus production and mucus plugging are common problems during both acute asthma exacerbation and in chronic asthma management.
  • Excess mucus in the airways increases the resistance to airflow through the airways by physically blocking all or part of the airway.
  • Excess mucus may also contribute to increased numbers of leukocytes found in airways of asthmatic patients by trapping leukocytes. Thus, excess mucus can increase chronic inflammation of the airways.
  • One type of asthma therapy involves treatment of the airways with energy to target and reduce the amount of mucus producing cells and glands and to reduce the effectiveness of the remaining mucus producing cells and glands.
  • the treatment can eliminate all or a portion of the mucus producing cells and glands, can prevent the cells from replicating or can inhibit their ability to secrete mucus. This treatment will have both chronic benefits in increasing airflow through the airways and will lessen the severity of acute exacerbation of the symptoms of reversible obstructive pulmonary disease.
  • FIGS. 1 and 2 illustrate cross sections of two different airways in a healthy patient.
  • the airway of FIG. 1 is a medium sized bronchus having an airway diameter D 1 of about 3 mm.
  • FIG. 2 shows a section through a bronchiole having an airway diameter D 2 of about 1.5 mm.
  • Each airway includes a folded inner surface or epithelium 10 surrounded by stroma 12 and smooth muscle tissue 14 .
  • the larger airways including the bronchus shown in FIG. 1 also have mucous glands 16 and cartilage 18 surrounding the smooth muscle tissue 14 . Nerve fibers 20 and blood vessels 24 also surround the airway.
  • FIG. 3 illustrates the bronchus of FIG. 1 in which the smooth muscle 14 has hypertrophied and increased in thickness causing the airway diameter to be reduced from the diameter D 1 to a diameter D 3 .
  • FIG. 4 is a schematic side view of the lungs being treated with a treatment device 38 according to the present invention.
  • the treatment device 38 is an elongated member for treating tissue at a treatment site 34 within a lung.
  • the invention discusses treatment of tissue at the surface it is also intended that the invention include treatment below an epithelial layer of the lung tissue.
  • the treatment of an airway with the treatment device may involve placing a visualization system such as an endoscope or bronchoscope into the airways.
  • the treatment device is then inserted through or next to the bronchoscope or endoscope while visualizing the airways.
  • the visualization system may be built directly into the treatment device using fiber optic imaging and lenses or a CCD and lens arranged at the distal portion of the treatment device.
  • the treatment device may also be positioned using radiographic visualization such as fluoroscopy or other external visualization means.
  • the treatment device which has been positioned with a distal end within an airway to be treated is energized so that energy is applied to the tissue of the airway walls in a desired pattern and intensity.
  • the distal end of the treatment device may be moved through the airway in a uniform painting like motion to expose the entire length of an airway to be treated to the energy.
  • the treatment device may be passed axially along the airway one or more times to achieve adequate treatment.
  • the “painting-like” motion used to exposed the entire length of an airway to the energy may be performed by moving the entire treatment device from the proximal end either manually or by motor. Alternatively, segments, stripes, rings or other treatment patterns may be used.
  • the energy is transferred to or from an airway wall in the opening region of the airway, preferably within a length of approximately two times the airway diameter or less, and to wall regions of airways distal to bifurcations and side branches, preferably within a distance of approximately twice the airway diameter or less.
  • the invention may also be used to treat long segments of un-bifurcated airway.
  • the invention includes a method of advancing a treatment device into a lung and treating the lung with the device to, at least, reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease.
  • the treatment may reduce all of the symptoms of reversible obstructive disease.
  • the treatment may be selected to address specific symptoms of the disease.
  • the treatment of the lung may sufficiently reduce the symptoms of reversible obstructive pulmonary disease such that the patient is able to function as those free from the disease.
  • the treatment may be such that the symptoms are reduced to allow the patient to more easily manage the disease.
  • the effects of the treatment may be either long term or short term with repeating treatment necessary to suppress the symptoms.
  • the methods of the invention described herein may be performed while the lung is experiencing natural symptoms of reversible obstructive pulmonary disease.
  • One such example is where an individual, experiencing an asthma attack, or acute exacerbation of asthma or COPD, undergoes treatment to improve the individual's ability to breath. In such a case, the treatment, called ‘rescue,’ seeks to provide immediate relief for the patient.
  • the method may also include the steps of locating one or more treatment sites within an airway of the lung, selecting one of the treatment sites from the locating step and treating at least one of the selected treatment sites. As mentioned above, these steps may be, but are not necessarily, performed while the lung is experiencing symptoms of reversible obstructive pulmonary disease.
  • the invention may further comprise the step of stimulating the lung to produce at least one artificially induced symptom of reversible obstructive pulmonary disease.
  • stimulation of the lung would preferably increase the resistance to airflow within the lung, constrict airways within the lung, inflame/irritate airway tissues, increase edema and/or increase the amount of mucus plugging of the airway.
  • Stimulation of the lung may occur at any point during the procedure or before the procedure.
  • the lung may be stimulated either prior to or after, the step of locating a treatment site. If the lung is stimulated prior to the step of locating a treatment site, the reaction of the stimulated tissue within the lung may be useful in determining which locations are to be selected as treatment sites.
  • the lung tissue or airway tissue within the lung may be stimulated by a variety of methods including but not limited to pharmacological stimulation, (e.g., histamine, methacholine, or other bronchoconstricting agents, etc.), electrical stimulation, mechanical stimulation, or any other stimuli causing obstructive pulmonary symptoms.
  • electrical stimulation may comprise exposing airway tissue to electrical field stimulation.
  • An example of such parameters include 15 VDC, 0.5 ms pulses, 0.5-16 Hz, and 70 VDC, 2-3 ms pulses, 20 HZ.
  • the locating step described above may be performed using a non-invasive imaging technique, including but not limited to, a bronchogram, magnetic resonance imaging, computed tomography, radiography (e.g., x-ray), and ventilation perfusion scans.
  • a non-invasive imaging technique including but not limited to, a bronchogram, magnetic resonance imaging, computed tomography, radiography (e.g., x-ray), and ventilation perfusion scans.
  • stimulation of the lung may occur prior to the step of testing the lung for pre-treatment pulmonary values.
  • the values would be determinative of pulmonary function values of a lung experiencing symptoms of reversible obstructive pulmonary disease.
  • the objective is to treat the lung until acceptable pulmonary function values are obtained.
  • One benefit of such a procedure is that the effect of the treatment on the patient is more readily observed as compared to the situation where a patient, having previously been treated, must wait for an attack of reversible obstructive pulmonary disease to determine the efficacy of the treatment.
  • FEV measures the volume of air exhaled over a pre-determined period of time by a forced expiration immediately after a full inspiration.
  • FVC measures the total volume of air exhaled immediately after a full inspiration.
  • Forced expiratory flow measures the volume of air exhaled during a FVC divided by the time in seconds.
  • Vmax is the maximum flow measured during FVC.
  • PEFR measures the maximum flow rate during a forced exhale starting from full inspiration.
  • RV is the volume of air remaining in the lungs after a full expiration.
  • the locating step described above may also comprise identifying treatment sites within the airway being susceptible to a symptom of reversible obstructive pulmonary disease.
  • symptoms may include, but are not limited to, airway inflammation, airway constriction, excessive mucous secretion, or any other asthmatic symptom. Stimulation of the lung to produce symptoms of reversible obstructive pulmonary disease may assist in identifying ideal treatment sites.
  • the method of the present invention may include stimulating the lung to produce at least one artificially induced symptom of reversible obstructive pulmonary disease and further include the step of evaluating the result of stimulation of the lung.
  • the evaluating step may include visually evaluating the effect of the stimulating step on the airway using a bronchoscope with a visualization system or by non-invasive imaging techniques, such as those describe herein.
  • the evaluating step may include measuring pressure changes in the airway before and after the stimulating step. Pressure may be measured globally (e.g., within the entire lung), or locally (e.g., within a specific section of the lung such as an airway or alveolar sac.)
  • the evaluating step may comprise measuring the electrical properties of the tissue before and after the stimulating step.
  • the invention may also include evaluating the results of the stimulating step by combining any of the methods previously mentioned. Also, the invention may further comprise the step of selecting at least one treatment parameter based upon the results of the evaluating step.
  • treatment parameters may include, but are not limited to, duration of treatment, intensity of treatment, temperature, amount of tissue treated, depth of treatment, etc.
  • the method may also include the step of determining the effect of the treatment by visually observing lung, airway or other such tissue for blanching of the tissue.
  • blanching is intended to include any physical change in tissue that is usually, but not necessarily, accompanied by a change in the color of the tissue.
  • One example of such blanching is where the tissue turns to a whitish color after the treatment of application of energy.
  • Another aspect of the invention includes advancing a treatment device into the lung and treating lung tissue to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease and further comprising the step of sub-mucosal sensing of the treatment to the lung tissue.
  • the sub-mucosal sensing may be invasive such as when using a probe equipped to monitor temperature, impedance, and/or blood flow. Or, the sub-mucosal sensing may be non-invasive in such cases as infra-red sensing.
  • the invention may also include using the treatment device to deposit radioactive substances at select treatment sites within the lung.
  • the radioactive substances including, but not limited to Iridium (e.g. 192 Ir.) either treat the lung tissue over time or provide treatment upon being deposited.
  • the invention also includes scraping epithelial tissue from the wall of an airway within the lung prior to advancing a treatment device into the lung to treat the lung tissue.
  • the removal of the epithelial tissue allows the device to treat the walls of an airway more effectively.
  • the invention further comprises the step of depositing a substance on the scraped wall of the airway after the device treats the airway wall.
  • the substance may include epithelial tissue, collagen, growth factors, or any other bio-compatible tissue or substance, which promotes healing, prevent infection, and/or assists in the clearing of mucus.
  • the treatment may comprise the act of scraping epithelial tissue to induce yield the desired response.
  • the invention may also include the additional step of reducing or stabilizing the temperature of lung tissue near to a treatment site. This may be accomplished for example, by injecting a cold fluid into lung parenchyma or into the airway being treated, where the airway is proximal, distal, or circumferentially adjacent to the treatment site.
  • the fluid may be sterile normal saline, or any other bio-compatible fluid.
  • the fluid may be injected into treatment regions within the lung while other regions of the lung normally ventilated by gas. Or, the fluid may be oxygenated to eliminate the need for alternate ventilation of the lung.
  • the fluid may be removed from the lungs.
  • the invention further includes methods of evaluating individuals having reversible obstructive pulmonary disease, or a symptom thereof, as a candidate for a procedure to reduce the ability of the individual's lung to produce at least one symptom of reversible obstructive pulmonary disease.
  • the method comprises the steps of assessing the pulmonary condition of the individual, comparing the pulmonary condition to a corresponding pre-determined state, and evaluate the individual as a candidate based upon the comparison.
  • the method of evaluating may further include the step of determining how the individual's tissue will react to treatment allowing the treatment to be tailored to the expected tissue response.
  • the method of evaluating may further comprises the step of pulmonary function testing using a gas, a mixture of gases, or a composition of several mixtures of gases to ventilate the lung.
  • the difference in properties of the gases may aid in the pulmonary function testing.
  • comparison of one or more pulmonary function test values that are obtained with the patient breathing gas mixtures of varying densities may help to diagnose lung function.
  • mixtures include air, at standard atmospheric conditions, and a mixture of helium and oxygen.
  • Additional examples of pulmonary testing include tests that measure capability and evenness of ventilation given diffusion of special gas mixtures.
  • gases used in the described tests include but are not limited to, nitrogen, carbon monoxide, carbon dioxide, and a range of inert gases.
  • the invention may also comprise the step of stimulating the lung to produce at least one artificially induced symptom of reversible obstructive pulmonary disease. Stimulating the symptoms of the disease in an individual allows the individual to be evaluated as the individual experiences the symptoms thereby allowing appropriate adjustment of the treatment.
  • the method of evaluating may also comprise the step of obtaining clinical information from the individual and accounting for the clinical information for treatment.
  • the method may further comprise the selection of a patient for treatment based upon a classification of the subtype of the patient's disease. For example, in asthma there are a number of ways to classify the disease state. One such method is the assessment of the severity of the disease. An example of a classification scheme by severity is found in the NHLBI Expert Panel 2 Guidelines for the Diagnosis and Treatment of Asthma .
  • Another selection method may include selecting a patient by the type of trigger that induces the exacerbation. Such triggers may be classified further by comparing allergic versus non-allergic triggers. For instance, an exercise induced bronchospasm (EIB) is an example of a non-allergenic trigger.
  • EIB exercise induced bronchospasm
  • the allergic sub-type may be further classified according to specific triggers (e.g., dust mites, animal dander, etc.). Another classification of the allergic sub-type may be according to characteristic features of the immune system response such as levels of IgE (a class of antibodies that function in allergic reactions, also called immunoglobulin). Yet another classification of allergic sub-types may be according to the expression of genes controlling certain interleukins (e.g., IL-4, IL-5, etc.) which have been shown to play a key role in certain types of asthma.
  • specific triggers e.g., dust mites, animal dander, etc.
  • Another classification of the allergic sub-type may be according to characteristic features of the immune system response such as levels of IgE (a class of antibodies that function in allergic reactions, also called immunoglobulin).
  • IgE a class of antibodies that function in allergic reactions, also called immunoglobulin
  • Yet another classification of allergic sub-types may be according to the expression of genes controlling certain interleukins (e.g.
  • This variation of the invention comprises obtaining clinical information, evaluating the clinical information with the results of the test to determine the effectiveness of the procedure. Furthermore, the variation may include stimulating the lung to produce a symptom of reversible obstructive pulmonary disease, assessing the pulmonary condition of the patient, then repeating the stimulation before the post-procedure pulmonary therapy. These steps allow comparison of the lung function when it is experiencing symptoms of reversible obstructive pulmonary disease, before and after the treatment, thereby allowing for an assessment of the improved efficiency of the lung during an attack of the disease.

Abstract

This relates to treating an asthmatic lung and more particularly, relates to advancing a treatment device into the lung and treating the lung with the device. This also includes additional steps of treating the airway wall, applying energy or heat to the airway wall in an asthmatic lung.

Description

  • This is a continuation of U.S. application Ser. No. 10/640,967 filed Aug. 13, 2003 which is a continuation of U.S. application Ser. No. 09/535,856 filed Mar. 27, 2000, now U.S. Pat. No. 6,634,363 which is a continuation-in-part application of U.S. application Ser. No. 09/296,040 filed Apr. 21, 1999 now U.S. Pat. No. 6,411,852, which is a continuation-in-part of U.S. application Ser. No. 09/095,323 filed Jun. 10, 1998; this is also a continuation-in-part application of U.S. application Ser. No. 09/436,455 filed Nov. 8, 1999 which is a continuation-in-part of U.S. application Ser. No. 09/095,323 filed Jun. 10, 1998 and is also a continuation-in-part of U.S. application Ser. No. 09/349,715 filed Jul. 8, 1999 now U.S. Pat. No. 6,488,675. All the above applications are incorporated by reference herein in their entirety.
  • BACKGROUND OF THE INVENTION
  • The invention relates to a method of treating a lung having at least one symptom of reversible obstructive pulmonary disease, and more particularly, the invention relates to advancing a treatment device into the lung and treating the lung with the device to at least reduce the ability of the lung to produce at least one of the symptoms of reversible obstructive pulmonary disease. The invention includes additional steps that reduce the ability of the lung to produce at least one of the symptoms of reversible obstructive pulmonary disease and to reduce the resistance to the flow of air through a lung.
  • Reversible obstructive pulmonary disease includes asthma and reversible aspects of chronic obstructive pulmonary disease (COPD). Asthma is a disease in which (i) bronchoconstriction, (ii) excessive mucus production, and (iii) inflammation and swelling of airways occur, causing widespread but variable airflow obstruction thereby making it difficult for the asthma sufferer to breathe. Asthma is a chronic disorder, primarily characterized by persistent airway inflammation. However, asthma is further characterized by acute episodes of additional airway narrowing via contraction of hyper-responsive airway smooth muscle.
  • The reversible aspects of COPD generally describe excessive mucus production in the bronchial tree. Usually, there is a general increase in bulk (hypertrophy) of the large bronchi and chronic inflammatory changes in the small airways. Excessive amounts of mucus are found in the airways and semisolid plugs of mucus may occlude some small bronchi. Also, the small airways are narrowed and show inflammatory changes. The reversible aspects of COPD include partial airway occlusion by excess secretions, and airway narrowing secondary to smooth muscle contraction, bronchial wall edema and inflation of the airways
  • In asthma, chronic inflammatory processes in the airway play a central role in increasing the resistance to airflow within the lungs. Many cells and cellular elements are involved in the inflammatory process, particularly mast cells, eosinophils T lymphocytes, neutrophils, epithelial cells, and even airway smooth muscle itself. The reactions of these cells result in an associated increase in the existing sensitivity and hyper-responsiveness of the airway smooth muscle cells that line the airways to the particular stimuli involved.
  • The chronic nature of asthma can also lead to remodeling of the airway wall (i.e., structural changes such as thickening or edema) which can further affect the function of the airway wall and influence airway hyper-responsiveness. Other physiologic changes associated with asthma include excess mucus production, and if the asthma is severe, mucus plugging, as well as ongoing epithelial denudation and repair. Epithelial denudation exposes the underlying tissue to substances that would not normally come in contact with them, further reinforcing the cycle of cellular damage and inflammatory response.
  • In susceptible individuals, asthma symptoms include recurrent episodes of shortness of breath (dyspnea), wheezing, chest tightness, and cough. Currently, asthma is managed by a combination of stimulus avoidance and pharmacology.
  • Stimulus avoidance is accomplished via systematic identification and minimization of contact with each type of stimuli. It may, however, be impractical and not always helpful to avoid all potential stimuli.
  • Asthma is managed pharmacologically by: (1) long term control through use of anti-inflammatories and long-acting bronchodilators and (2) short term management of acute exacerbations through use of short-acting bronchodilators. Both of these approaches require repeated and regular use of the prescribed drugs. High doses of corticosteroid anti-inflammatory drugs can have serious side effects that require careful management. In addition, some patients are resistant to steroid treatment. The difficulty involved in patient compliance with pharmacologic management and the difficulty of avoiding stimulus that triggers asthma are common barriers to successful asthma management.
  • Asthma is a serious disease with growing numbers of sufferers. Current management techniques are neither completely successful nor free from side effects.
  • Accordingly, it would be desirable to provide an asthma treatment which improves airflow without the need for patient compliance.
  • In addition to the airways of the lungs, other body conduits such as the esophagus, ureter, urethra, and coronary arteries, are also subject to periodic reversible spasms that produce obstruction to flow.
  • SUMMARY OF THE INVENTION
  • The present invention relates to methods for treating a lung, preferably having at least one symptom of reversible obstructive pulmonary disease, comprising the steps of advancing a treatment device into the lung and treating the lung with the device to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease and to decrease the resistance to the flow of air through the lung.
  • A variation of the invention includes the method described above further comprising the step of locating one or more treatment sites within an airway of the lung, selecting at least one of the treatment sites and treating at least one of the treatment sites selected in the selecting step. The invention may further include performing the steps while the lung is experiencing at least one symptom of either natural or artificially induced reversible obstructive pulmonary disease.
  • A further variation of the invention includes the method described above and further includes the steps of testing the lung for at least one pre-treatment pulmonary function value prior to the treating step, and re-testing the lung for at least one post-treatment pulmonary function value subsequent to the treating step.
  • A further variation of the invention includes the method described above further comprising identifying treatment sites within the airway being highly susceptible to either airway inflammation, airway constriction, excessive mucus secretion, or any other symptom of reversible obstructive pulmonary disease.
  • Another variation of the invention includes the method described above and the additional step of stimulating the lung to produce at least one artificially induced symptom of reversible obstructive pulmonary disease. The invention may further comprise the step of evaluating the results of the stimulating step.
  • Another variation of the invention includes the method described above where treating at least airway tissue within the lung further comprises the step of determining the effect of the treatment by visually observing the airway for blanching of airway tissue.
  • Another variation of the invention includes the method described above where treating at least airway tissue at a treatment site within the lung further comprises the step of monitoring electrical impedance of tissue at one or more points.
  • Another variation of the invention includes the method described above where treating the lung includes sub-mucosal treatment of at least airway tissue in the lung.
  • Another variation of the invention includes the method described above where the treating step includes treating the lung by depositing a radioactive substance in at least one treatment site within the lung.
  • Another variation of the invention include the method described above further including the step of scraping tissue from a wall of an airway within the lung prior to the treating step. The invention may further comprise depositing a substance on the scraped wall of the airway.
  • Another variation of the invention includes the method described above where the treating step uses a modality selected from the group consisting of mechanical, chemical, radio frequency, radioactive energy, heat, and ultrasound.
  • Another variation of the invention includes the method described above further comprising pre-treating the lung to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease prior to the treating step, where at least one parameter of the pre-treating step is lesser than at least one parameter of the treating step.
  • Another variation of the invention comprises the method described above where the treating step includes separating the treating step into stages to reduce the healing load on the lung. The separating step may comprise treating different regions of the lung at different times or dividing the number of treatment sites into a plurality of groups of treatment sites and treating each group at a different time.
  • Another variation of the invention includes the method described above further comprising sensing movement of the lung and repositioning the treatment device in response to said sensing step.
  • Another variation of the invention includes the method described above further comprising reducing the temperature of lung tissue adjacent to a treatment site.
  • Another variation of the invention includes the method described above further comprising the step of providing drug therapy, exercise therapy, respiratory therapy, and/or education on disease management techniques to further reduce the effects of reversible obstructive pulmonary disease.
  • The invention further includes the method for reversing a treatment to reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease comprising the step of stimulating re-growth of smooth muscle tissue in the lung.
  • The invention further includes the method of evaluating an individual having reversible obstructive pulmonary disease as a candidate for a procedure to reduce the ability of the individual's lung to produce at least one reversible obstructive pulmonary disease symptom by treating an airway within the lung of the individual, the method comprising the steps of assessing the pulmonary condition of the individual, comparing the pulmonary condition to a corresponding predetermined state; and evaluating the individual based upon the comparing step. The method may additionally comprise the steps of performing pulmonary function tests on the individual to obtain at least one pulmonary function value, comparing the at least one pulmonary function value to a corresponding predetermined pulmonary function value, and evaluating the individual based upon the comparing step.
  • The invention further comprises a method of evaluating the effectiveness of a procedure to reduce the ability of lung to produce at least one symptom of reversible obstructive pulmonary disease previously performed on an individual having reversible obstructive pulmonary disease, the method comprising the steps of assessing the pulmonary condition of the individual, comparing the pulmonary condition to a corresponding predetermined state; and evaluating the effectiveness of the procedure based upon the comparing step. The method may additionally comprise the steps of performing pulmonary function tests on the individual to obtain at least one pulmonary function value, treating the lung to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease, performing post-procedure pulmonary function tests on the individual to obtain at least one post-procedure pulmonary function value; and comparing the pulmonary function value with the post-procedure pulmonary function value to determine the effect of the treating step.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The invention will now be described in greater detail with reference to the various embodiments illustrated in the accompanying drawings:
  • FIG. 1. is a cross sectional view of an airway in a healthy lung.
  • FIG. 2. shows a section through a bronchiole having an airway diameter smaller than that shown in FIG. 1.
  • FIG. 3 illustrates the airway of FIG. 1 in which the smooth muscle 14 has hypertrophied and increased in thickness causing reduction of the airway diameter.
  • FIG. 4 is a schematic side view of the lungs being treated with a treatment device 38 as described herein.
  • DETAILED DESCRIPTION
  • The invention relates to methods for improving airflow through the airways of a lung having reversible obstructive pulmonary disease. It is intended that the invention is applicable to any aspect of reversible obstructive pulmonary disease, including but not limited to asthma. One way of improving airflow is to decrease the resistance to airflow within the lungs. There are several approaches to reducing this resistance, including but not limited to reducing the ability of the airway to contract, increasing the airway diameter, reducing the inflammation of airway tissues, and/or reducing the amount of mucus plugging of the airway. The present invention includes advancing a treatment device into the lung and treating the lung to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease. The following is a brief discussion of some causes of increased resistance to airflow within the lungs and the inventive treatment of the invention described herein. As such, the following discussion is not intended to limit the aspects or objective of the inventive method as the inventive method may cause physiological changes not described below but such changes still contributing to reducing or eliminating at least one of the symptoms of reversible obstructive pulmonary disease.
  • Reducing the Ability of the Airway to Contract
  • The inventive treatment reduces the ability of the airways to narrow or to reduce in diameter due to airway smooth muscle contraction. The inventive treatment uses a modality of treatments including, but not limited to the following: chemical, radio frequency, radioactivity, heat, ultrasound, radiant, laser, microwave, or mechanical energy (such as in the form of cutting, punching, abrading, rubbing, or dilating). This treatment reduces the ability of the smooth muscle to contract thereby lessening the severity of an asthma attack. The reduction in the ability of the smooth muscle to contract may be achieved by treating the smooth muscle itself or by treating other tissues which in turn influence smooth muscle contraction or the response of the airway to the smooth muscle contraction. Treatment may also reduce airway responsiveness or the tendency of the airway to narrow or to constrict in response to a stimulus.
  • The amount of smooth muscle surrounding the airway can be reduced by exposing the smooth muscle to energy which either kills the muscle cells or prevents these cells from replicating. The reduction in smooth muscle reduces the ability of the smooth muscle to contract and to narrow the airway during a spasm. The reduction in smooth muscle and surrounding tissue has the added potential benefit of increasing the caliber or diameter of the airways, this benefit reduces the resistance to airflow through the airways. In addition to the use of debulking smooth muscle tissue to open up the airways, the device used in the present invention may also eliminate smooth muscle altogether by damaging or destroying the muscle. The elimination of the smooth muscle prevents the contraction or spasms of hyper-reactive airways of a patient having reversible obstructive pulmonary disease. By doing so, the elimination of the smooth muscle may reduce some symptoms of reversible obstructive pulmonary disease.
  • The ability of the airway to contract can also be altered by treatment of the smooth muscle in particular patterns. The smooth muscle is arranged around the airways in a generally helical pattern with pitch angles ranging from about −38 to about +38 degrees. Thus, the treatment of the smooth muscle in appropriate patterns interrupts or cuts through the helical pattern of the smooth muscle at a proper pitch and prevents the airway from constricting. This procedure of patterned treatment application eliminates contraction of the airways without completely eradicating smooth muscle and other airway tissue. A pattern for treatment may be chosen from a variety of patterns including longitudinal or axial stripes, circumferential bands, helical stripes, and the like as well as spot patterns having rectangular, elliptical, circular or other shapes. The size, number, and spacing of the treatment bands, stripes, or spots are chosen to provide a desired clinical effect of reduced airway responsiveness while limiting insult to the airway to a clinically acceptable level.
  • The patterned treatment of the tissues surrounding the airways with energy provides various advantages. The careful selection of the portion of the airway to be treated allows desired results to be achieved while reducing the total healing load. Patterned treatment can also achieve desired results with decreased morbidity, preservation of epithelium, and preservation of a continuous or near continuous ciliated inner surface of the airway for mucociliary clearance. The pattern of treatment may also be chosen to achieve desired results while limiting total treatment area and/or the number of airways treated, thereby improving speed and ease of treatment.
  • Application of energy to the tissue surrounding the airways may also cause the DNA of the cells to become cross linked. The treated cells with cross linked DNA are incapable of replicating. Accordingly, over time, as the smooth muscle cells die, the total thickness of smooth muscle decreases because of the inability of the cells to replicate. The programmed cell death causing a reduction in the volume of tissue is called apoptosis. This treatment does not cause an immediate effect but causes shrinking of the smooth muscle and opening of the airway over time and substantially prevents re-growth. The application of energy to the walls of the airway may also be used to cause a cross linking of the DNA of the mucus gland cells thereby preventing them from replicating and reducing excess mucus plugging or production over time.
  • The ability of the airways to contract may also be reduced by altering mechanical properties of the airway wall, such as by increasing stiffness of the wall or by increasing parenchymal tethering of the airway wall. Both of these methods increase the strength of the airway wall and further oppose contraction and narrowing of the airway.
  • There are several ways to increase the stiffness of the airway wall. One way to increase stiffness is to induce fibrosis or a wound healing response by causing trauma to the airway wall. The trauma can be caused by delivery of therapeutic energy to the tissue in the airway wall, by mechanical insult to the tissue, or by chemically affecting the tissue. The energy is preferably delivered in such a way that it minimizes or limits the intra-luminal thickening that may occur.
  • Another way to increase the effective stiffness of the airway wall is to alter the submucosal folding of the airway upon narrowing. The mucosal layer includes the epithelium, its basement membrane, and the lamina propria, a subepithelial collagen layer. The submucosal layer may also play a role in airway folding. As an airway narrows, its perimeter remains relatively constant, with the mucosal layer folding upon itself. As the airway narrows further, the mucosal folds mechanically interfere with each other, effectively stiffening the airway. In asthmatic patients, the number of folds is fewer and the size of the folds is larger, and thus, the airway is free to narrow with less mechanical interference of mucosal folds than in a healthy patient. Thus, asthmatic patients have a decrease in airway stiffness and the airways have less resistance to narrowing.
  • The mucosal folding in asthmatic patients can be improved by treatment of the airway in a manner which encourages folding. Preferably, a treatment will increase the number of folds and/or decrease the size of the folds in the mucosal layer. For example, treatment of the airway wall in a pattern such as longitudinal stripes can encourage greater number of smaller mucosal folds and increase airway stiffness.
  • The mucosal folding can also be increased by encouraging a greater number of smaller folds by reducing the thickness of the mucosa and/or submucosal layer. The decreased thickness of the mucosa or submucosa may be achieved by application of energy which either reduces the number of cells in the mucosa or submucosal layer or which prevents replication of the cells in the mucosa or submucosal layer. A thinner mucosa or submucosal layer will have an increased tendency to fold and increased mechanical stiffening caused by the folds.
  • Another way to reduce the ability of the airways to contract is to improve parenchymal tethering. The parenchyma surrounds airways and includes the alveolus and tissue connected to and surrounding the outer portion of the airway wall. The parenchyma includes the alveolus and tissue connected to and surrounding the cartilage that supports the larger airways. In a healthy patient, the parenchyma provides a tissue network which connects to and helps to support the airway. Edema or accumulation of fluid in lung tissue in patients with asthma or COPD is believed to decouple the airway from the parenchyma reducing the restraining force of the parenchyma which opposes airway constriction. Energy can be used to treat the parenchyma to reduce edema and/or improve parenchymal tethering.
  • In addition, the applied energy may be used to improve connection between the airway smooth muscle and submucosal layer to the surrounding cartilage, and to encourage wound healing, collagen deposition, and/or fibrosis in the tissue surrounding the airway to help support the airway and prevent airway contraction.
  • Increasing the Airway Diameter
  • Hypertrophy of smooth muscle, chronic inflammation of airway tissues, and general thickening of all parts of the airway wall can reduce the airway diameter in patients with reversible obstructive pulmonary disease. Increasing the overall airway diameter using a variety of techniques can improve the passage of air through the airways. Application of energy to the airway smooth muscle of an asthmatic patient can debulk or reduce the volume of smooth muscle. This reduced volume of smooth muscle increases the airway diameter for improved air exchange.
  • Reducing inflammation and edema of the tissue surrounding the airway can also increase the diameter of an airway. Inflammation and edema (accumulation of fluid) of the airway are chronic features of asthma. The inflammation and edema can be reduced by application of energy to stimulate wound healing and regenerate normal tissue. Healing of the epithelium or sections of the epithelium experiencing ongoing denudation and renewal allows regeneration of healthy epithelium with less associated airway inflammation. The less inflamed airway has an increased airway diameter both at a resting state and in constriction. The wound healing can also deposit collagen which improves parenchymal tethering.
  • Inflammatory mediators released by tissue in the airway wall may serve as a stimulus for airway smooth muscle contraction. Therapy that reduces the production and release of inflammatory mediator can reduce smooth muscle contraction, inflammation of the airways, and edema. Examples of inflammatory mediators are cytokines, chemokines, and histamine. The tissues which produce and release inflammatory mediators include airway smooth muscle, epithelium, and mast cells. Treatment of these structures with energy can reduce the ability of the airway structures to produce or release inflammatory mediators. The reduction in released inflammatory mediators will reduce chronic inflammation, thereby increasing the airway inner diameter, and may also reduce hyper-responsiveness of the airway smooth muscle.
  • A further process for increasing the airway diameter is by denervation. A resting tone of smooth muscle is nerve regulated by release of catecholamines. Thus, by damaging or eliminating nerve tissue in the airways the resting tone of the smooth muscle is reduced, and the airway diameter is increased. Resting tone may also be reduced by directly affecting the ability of smooth muscle tissue to contract.
  • Reducing Plugging of the Airway
  • Excess mucus production and mucus plugging are common problems during both acute asthma exacerbation and in chronic asthma management. Excess mucus in the airways increases the resistance to airflow through the airways by physically blocking all or part of the airway. Excess mucus may also contribute to increased numbers of leukocytes found in airways of asthmatic patients by trapping leukocytes. Thus, excess mucus can increase chronic inflammation of the airways.
  • One type of asthma therapy involves treatment of the airways with energy to target and reduce the amount of mucus producing cells and glands and to reduce the effectiveness of the remaining mucus producing cells and glands. The treatment can eliminate all or a portion of the mucus producing cells and glands, can prevent the cells from replicating or can inhibit their ability to secrete mucus. This treatment will have both chronic benefits in increasing airflow through the airways and will lessen the severity of acute exacerbation of the symptoms of reversible obstructive pulmonary disease.
  • Application of Treatment
  • The following illustrations are examples of the invention described herein. It is contemplated that combinations of aspects of specific embodiments or combinations of the specific embodiments themselves are within the scope of this disclosure.
  • FIGS. 1 and 2 illustrate cross sections of two different airways in a healthy patient. The airway of FIG. 1 is a medium sized bronchus having an airway diameter D1 of about 3 mm. FIG. 2 shows a section through a bronchiole having an airway diameter D2 of about 1.5 mm. Each airway includes a folded inner surface or epithelium 10 surrounded by stroma 12 and smooth muscle tissue 14. The larger airways including the bronchus shown in FIG. 1 also have mucous glands 16 and cartilage 18 surrounding the smooth muscle tissue 14. Nerve fibers 20 and blood vessels 24 also surround the airway.
  • FIG. 3 illustrates the bronchus of FIG. 1 in which the smooth muscle 14 has hypertrophied and increased in thickness causing the airway diameter to be reduced from the diameter D1 to a diameter D3.
  • FIG. 4 is a schematic side view of the lungs being treated with a treatment device 38 according to the present invention. The treatment device 38 is an elongated member for treating tissue at a treatment site 34 within a lung. Although the invention discusses treatment of tissue at the surface it is also intended that the invention include treatment below an epithelial layer of the lung tissue.
  • An example of devices for use with the methods of this invention are found in the following U.S. patent application Ser. No. 09/095,323—Methods and Apparatus for Treating Smooth Muscles in the Walls of Body Conduits; Ser. No. 09/349,715—Method of Increasing Gas Exchange of a Lung now U.S. Pat. No. 6,488,675; and Ser. No. 09/296,040—Devices for Modification of Airways By Transfer of Energy now U.S. Pat. No. 6,411,852; Ser. No. 09/436,455 Devices for Modification of Airways by Transfer of Energy. The entirety of each of the aforementioned applications is incorporated by reference herein.
  • The treatment of an airway with the treatment device may involve placing a visualization system such as an endoscope or bronchoscope into the airways. The treatment device is then inserted through or next to the bronchoscope or endoscope while visualizing the airways. Alternatively, the visualization system may be built directly into the treatment device using fiber optic imaging and lenses or a CCD and lens arranged at the distal portion of the treatment device. The treatment device may also be positioned using radiographic visualization such as fluoroscopy or other external visualization means. The treatment device which has been positioned with a distal end within an airway to be treated is energized so that energy is applied to the tissue of the airway walls in a desired pattern and intensity. The distal end of the treatment device may be moved through the airway in a uniform painting like motion to expose the entire length of an airway to be treated to the energy. The treatment device may be passed axially along the airway one or more times to achieve adequate treatment. The “painting-like” motion used to exposed the entire length of an airway to the energy may be performed by moving the entire treatment device from the proximal end either manually or by motor. Alternatively, segments, stripes, rings or other treatment patterns may be used.
  • According to one variation of the invention, the energy is transferred to or from an airway wall in the opening region of the airway, preferably within a length of approximately two times the airway diameter or less, and to wall regions of airways distal to bifurcations and side branches, preferably within a distance of approximately twice the airway diameter or less. The invention may also be used to treat long segments of un-bifurcated airway.
  • The invention includes a method of advancing a treatment device into a lung and treating the lung with the device to, at least, reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease. It is contemplated that the treatment may reduce all of the symptoms of reversible obstructive disease. Alternatively, the treatment may be selected to address specific symptoms of the disease. It is also intended that the treatment of the lung may sufficiently reduce the symptoms of reversible obstructive pulmonary disease such that the patient is able to function as those free from the disease. Alternatively, the treatment may be such that the symptoms are reduced to allow the patient to more easily manage the disease. It is also intended that the effects of the treatment may be either long term or short term with repeating treatment necessary to suppress the symptoms.
  • The methods of the invention described herein may be performed while the lung is experiencing natural symptoms of reversible obstructive pulmonary disease. One such example is where an individual, experiencing an asthma attack, or acute exacerbation of asthma or COPD, undergoes treatment to improve the individual's ability to breath. In such a case, the treatment, called ‘rescue,’ seeks to provide immediate relief for the patient.
  • The method may also include the steps of locating one or more treatment sites within an airway of the lung, selecting one of the treatment sites from the locating step and treating at least one of the selected treatment sites. As mentioned above, these steps may be, but are not necessarily, performed while the lung is experiencing symptoms of reversible obstructive pulmonary disease.
  • The invention may further comprise the step of stimulating the lung to produce at least one artificially induced symptom of reversible obstructive pulmonary disease. For example, stimulation of the lung would preferably increase the resistance to airflow within the lung, constrict airways within the lung, inflame/irritate airway tissues, increase edema and/or increase the amount of mucus plugging of the airway. Stimulation of the lung may occur at any point during the procedure or before the procedure. For example, the lung may be stimulated either prior to or after, the step of locating a treatment site. If the lung is stimulated prior to the step of locating a treatment site, the reaction of the stimulated tissue within the lung may be useful in determining which locations are to be selected as treatment sites. The lung tissue or airway tissue within the lung may be stimulated by a variety of methods including but not limited to pharmacological stimulation, (e.g., histamine, methacholine, or other bronchoconstricting agents, etc.), electrical stimulation, mechanical stimulation, or any other stimuli causing obstructive pulmonary symptoms. For example, electrical stimulation may comprise exposing airway tissue to electrical field stimulation. An example of such parameters include 15 VDC, 0.5 ms pulses, 0.5-16 Hz, and 70 VDC, 2-3 ms pulses, 20 HZ.
  • The locating step described above may be performed using a non-invasive imaging technique, including but not limited to, a bronchogram, magnetic resonance imaging, computed tomography, radiography (e.g., x-ray), and ventilation perfusion scans.
  • The invention further includes the steps of testing the lung for at least one pre-treatment pulmonary function value prior to treating the lung with the device. After the lung is treated, the lung is re-tested for at least one post-treatment pulmonary function value. Naturally, the two pulmonary function values may be compared to estimate the effect of the treatment. The invention may also include treating additional sites in the lung after the re-testing step to at least reduce the effect of at least one symptom of reversible obstructive pulmonary disease. The invention may also include stimulating the lung to produce at least one artificially induced symptom of reversible obstructive pulmonary disease. As mentioned above, the stimulation of the lung may occur at any point during, or prior to, the procedure. For example, stimulation of the lung may occur prior to the step of testing the lung for pre-treatment pulmonary values. In this case, the values would be determinative of pulmonary function values of a lung experiencing symptoms of reversible obstructive pulmonary disease. Accordingly, the objective is to treat the lung until acceptable pulmonary function values are obtained. One benefit of such a procedure is that the effect of the treatment on the patient is more readily observed as compared to the situation where a patient, having previously been treated, must wait for an attack of reversible obstructive pulmonary disease to determine the efficacy of the treatment.
  • Pulmonary function values are well known in the art. The following is an example of pulmonary function values that may be used. Other pulmonary function values, or combinations thereof, are intended to be within the scope of this invention. The values include, but are not limited to, FEV (forced expiratory volume), FVC (forced vital capacity), FEF (forced expiratory flow), Vmax (maximum flow), PEFR (peak expiratory flow rate), FRC (functional residual capacity), RV (residual volume), TLC (total lung capacity).
  • FEV measures the volume of air exhaled over a pre-determined period of time by a forced expiration immediately after a full inspiration. FVC measures the total volume of air exhaled immediately after a full inspiration. Forced expiratory flow measures the volume of air exhaled during a FVC divided by the time in seconds. Vmax is the maximum flow measured during FVC. PEFR measures the maximum flow rate during a forced exhale starting from full inspiration. RV is the volume of air remaining in the lungs after a full expiration.
  • The locating step described above may also comprise identifying treatment sites within the airway being susceptible to a symptom of reversible obstructive pulmonary disease. For example, symptoms may include, but are not limited to, airway inflammation, airway constriction, excessive mucous secretion, or any other asthmatic symptom. Stimulation of the lung to produce symptoms of reversible obstructive pulmonary disease may assist in identifying ideal treatment sites.
  • As noted above, the method of the present invention may include stimulating the lung to produce at least one artificially induced symptom of reversible obstructive pulmonary disease and further include the step of evaluating the result of stimulation of the lung. For example, the evaluating step may include visually evaluating the effect of the stimulating step on the airway using a bronchoscope with a visualization system or by non-invasive imaging techniques, such as those describe herein. The evaluating step may include measuring pressure changes in the airway before and after the stimulating step. Pressure may be measured globally (e.g., within the entire lung), or locally (e.g., within a specific section of the lung such as an airway or alveolar sac.) Also, the evaluating step may comprise measuring the electrical properties of the tissue before and after the stimulating step. The invention may also include evaluating the results of the stimulating step by combining any of the methods previously mentioned. Also, the invention may further comprise the step of selecting at least one treatment parameter based upon the results of the evaluating step. Such treatment parameters may include, but are not limited to, duration of treatment, intensity of treatment, temperature, amount of tissue treated, depth of treatment, etc.
  • The method may also include the step of determining the effect of the treatment by visually observing lung, airway or other such tissue for blanching of the tissue. The term “blanching” is intended to include any physical change in tissue that is usually, but not necessarily, accompanied by a change in the color of the tissue. One example of such blanching is where the tissue turns to a whitish color after the treatment of application of energy.
  • The invention may also include the step of monitoring impedance across a treated area of tissue within the lung. Measuring impedance may be performed in cases of monopolar or bipolar energy delivery devices. Additionally, impedance may be monitored at more than one site within the lungs. The measuring of impedance may be, but is not necessarily, performed by the same electrodes used to deliver the energy treatment to the tissue. Furthermore, the invention includes adjusting the treatment parameters based upon the monitoring of the change in impedance after the treatment step. For example, as the energy treatment affects the properties of the treated tissue, measuring changes in impedance may provide information useful in adjusting treatment parameters to obtain a desired result.
  • Another aspect of the invention includes advancing a treatment device into the lung and treating lung tissue to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease and further comprising the step of sub-mucosal sensing of the treatment to the lung tissue. The sub-mucosal sensing may be invasive such as when using a probe equipped to monitor temperature, impedance, and/or blood flow. Or, the sub-mucosal sensing may be non-invasive in such cases as infra-red sensing.
  • The invention may also include using the treatment device to deposit radioactive substances at select treatment sites within the lung. The radioactive substances, including, but not limited to Iridium (e.g. 192Ir.) either treat the lung tissue over time or provide treatment upon being deposited.
  • The invention also includes scraping epithelial tissue from the wall of an airway within the lung prior to advancing a treatment device into the lung to treat the lung tissue. The removal of the epithelial tissue allows the device to treat the walls of an airway more effectively. The invention further comprises the step of depositing a substance on the scraped wall of the airway after the device treats the airway wall. The substance may include epithelial tissue, collagen, growth factors, or any other bio-compatible tissue or substance, which promotes healing, prevent infection, and/or assists in the clearing of mucus. Alternatively, the treatment may comprise the act of scraping epithelial tissue to induce yield the desired response.
  • The invention includes using the treating device to pre-treat the lung to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease prior to the treating step. At least one of the parameters of the pre-treating step may differ than one of the parameters of the treating step. Such parameters may include time, temperature, amount of tissue over which treatment is applied, amount of energy applied, depth of treatment, etc.
  • The invention may also include advancing the treatment device into the lung and treating the lung tissue in separate stages. One of the benefits of dividing the treating step into separate stages is that the healing load of the patient is lessened. Dividing of the treating step may be accomplished by treating different regions of the lung at different times. Or, the total number of treatment sites may be divided into a plurality of groups of treatment sites, where each group of treatment sites is treated at a different time. The amount of time between treatments may be chosen such that the healing load placed on the lungs is minimized.
  • The invention may also include advancing a treatment device into the lung, treating the lung with the device and sensing movement of the lung to reposition the treatment device in response to the movement. This sensing step accounts for the tidal motion of the lung during breathing cycles or other movement. Taking into account the tidal motion allows improved accuracy in repositioning of the device at a desired target.
  • The invention may also include the additional step of reducing or stabilizing the temperature of lung tissue near to a treatment site. This may be accomplished for example, by injecting a cold fluid into lung parenchyma or into the airway being treated, where the airway is proximal, distal, or circumferentially adjacent to the treatment site. The fluid may be sterile normal saline, or any other bio-compatible fluid. The fluid may be injected into treatment regions within the lung while other regions of the lung normally ventilated by gas. Or, the fluid may be oxygenated to eliminate the need for alternate ventilation of the lung. Upon achieving the desired reduction or stabilization of temperature the fluid may be removed from the lungs. In the case where a gas is used to reduce temperature, the gas may be removed from the lung or allowed to be naturally exhaled. One benefit of reducing or stabilizing the temperature of the lung may be to prevent excessive destruction of the tissue, or to prevent destruction of certain types of tissue such as the epithelium, or to reduce the systemic healing load upon the patient's lung.
  • Also contemplated as within the scope of the invention is the additional step of providing therapy to further reduce the effects of reversible obstructive pulmonary disease or which aids the healing process after such treatment. Some examples of therapy include, drug therapy, exercise therapy, and respiratory therapy. The invention further includes providing education on reversible obstructive pulmonary disease management techniques to further reduce the effects of the disease. For example, such techniques may be instruction on lifestyle changes, self-monitoring techniques to assess the state of the disease, and/or medication compliance education.
  • There may be occurrences where it is necessary to reverse the effects of the treatment described herein. Accordingly, the invention further includes a method for reversing a treatment to reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease comprising the step of stimulating re-growth of smooth muscle tissue. The re-stimulation of the muscle may be accomplished by the use of electro-stimulation, exercising of the muscle and/or drug therapy.
  • The invention further includes methods of evaluating individuals having reversible obstructive pulmonary disease, or a symptom thereof, as a candidate for a procedure to reduce the ability of the individual's lung to produce at least one symptom of reversible obstructive pulmonary disease. The method comprises the steps of assessing the pulmonary condition of the individual, comparing the pulmonary condition to a corresponding pre-determined state, and evaluate the individual as a candidate based upon the comparison.
  • In assessing the pulmonary condition, the method may comprise the steps of performing pulmonary function tests on the individual to obtain a pulmonary function value which is compared to a predetermined value. Examples of pre-determined values are found above.
  • The method of evaluating may further include the step of determining how the individual's tissue will react to treatment allowing the treatment to be tailored to the expected tissue response.
  • The method of evaluating may further comprises the step of pulmonary function testing using a gas, a mixture of gases, or a composition of several mixtures of gases to ventilate the lung. The difference in properties of the gases may aid in the pulmonary function testing. For example, comparison of one or more pulmonary function test values that are obtained with the patient breathing gas mixtures of varying densities may help to diagnose lung function. Examples of such mixtures include air, at standard atmospheric conditions, and a mixture of helium and oxygen. Additional examples of pulmonary testing include tests that measure capability and evenness of ventilation given diffusion of special gas mixtures. Other examples of gases used in the described tests, include but are not limited to, nitrogen, carbon monoxide, carbon dioxide, and a range of inert gases.
  • The invention may also comprise the step of stimulating the lung to produce at least one artificially induced symptom of reversible obstructive pulmonary disease. Stimulating the symptoms of the disease in an individual allows the individual to be evaluated as the individual experiences the symptoms thereby allowing appropriate adjustment of the treatment.
  • The method of evaluating may also comprise the step of obtaining clinical information from the individual and accounting for the clinical information for treatment.
  • The method may further comprise the selection of a patient for treatment based upon a classification of the subtype of the patient's disease. For example, in asthma there are a number of ways to classify the disease state. One such method is the assessment of the severity of the disease. An example of a classification scheme by severity is found in the NHLBI Expert Panel 2 Guidelines for the Diagnosis and Treatment of Asthma. Another selection method may include selecting a patient by the type of trigger that induces the exacerbation. Such triggers may be classified further by comparing allergic versus non-allergic triggers. For instance, an exercise induced bronchospasm (EIB) is an example of a non-allergenic trigger. The allergic sub-type may be further classified according to specific triggers (e.g., dust mites, animal dander, etc.). Another classification of the allergic sub-type may be according to characteristic features of the immune system response such as levels of IgE (a class of antibodies that function in allergic reactions, also called immunoglobulin). Yet another classification of allergic sub-types may be according to the expression of genes controlling certain interleukins (e.g., IL-4, IL-5, etc.) which have been shown to play a key role in certain types of asthma.
  • The invention further comprises methods to determine the completion of the procedure and the effectiveness of the reduction in the lung's ability to produce at least one symptom of reversible obstructive pulmonary disease. This variation of the invention comprises assessing the pulmonary condition of the individual, comparing the pulmonary condition to a corresponding predetermined state, and evaluating the effectiveness of the procedure based on the comparison. The invention may also comprise the steps of performing pulmonary function tests on the individual to obtain at least one pulmonary function value, treating the lung to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease, performing a post-procedure pulmonary function tests on the individual to obtain at least one post pulmonary function value and comparing the two values.
  • This variation of the invention comprises obtaining clinical information, evaluating the clinical information with the results of the test to determine the effectiveness of the procedure. Furthermore, the variation may include stimulating the lung to produce a symptom of reversible obstructive pulmonary disease, assessing the pulmonary condition of the patient, then repeating the stimulation before the post-procedure pulmonary therapy. These steps allow comparison of the lung function when it is experiencing symptoms of reversible obstructive pulmonary disease, before and after the treatment, thereby allowing for an assessment of the improved efficiency of the lung during an attack of the disease.
  • The invention herein is described by examples and a desired way of practicing the invention is described. However, the invention as claimed herein is not limited to that specific description in any manner. Equivalence to the description as hereinafter claimed is considered to be within the scope of protection of this patent.

Claims (13)

1. A method for reducing inflammation of airway tissue in the lungs, the method comprising:
providing an energy transfer device;
transferring energy from the energy transfer device to or from airway tissue in an airway wall to reduce the inflammatory response of the airway tissue.
2. The method of claim 1, where the airway tissue is tissue selected from the group consisting of airway smooth muscle, epithelium, and mast cells.
3. The method of claim 1, where the energy transfer disrupts the inflammatory response by altering production or release of inflammatory mediators in at least a part of the airway.
4. The method of claim 1, where the energy transfer disrupts the inflammatory response by preventing replication of structures producing or releasing inflammatory mediators.
5. The method of claim 1, where the energy transfer disrupts the inflammatory response by eliminating at least a portion of the structures which produce or release inflammatory mediators.
6. The method of claim 5, where the energy transfer disrupts the inflammatory response by altering the ability of structures in the airway to produce or release inflammatory mediators.
7. The method of claim 1, where the energy is selected from a modality selected from the group consisting of mechanical, chemical, radio frequency, radioactive energy, heat, and ultrasound.
8. The method of claim 1, where transferring energy from the energy transfer device comprises moving the energy transfer device along the airway.
9. The method of claim 1, where the energy is transferred to a portion of the airway by an energy transfer device to create one or more energy transfer patterns.
10. The method of claim 9, where the energy transfer pattern is a pattern of one or more spots having a rectangular, elliptical, circular, or other shape.
11. The method of claim 9, where the energy is transferred to the airway in a band pattern covering a full diameter of the airway.
12. The method of claim 9, where the energy is transferred to the airway in a pattern of at least one stripe extending along the airway in a longitudinal or helical pattern.
13. The method of claim 1, where the energy is transferred to the airway by activating an energy transfer device, deactivating the energy transfer device, moving the energy transfer device, and reactivating the energy transfer device.
US11/421,444 1998-06-10 2006-05-31 Methods of treating inflammation in airways Expired - Lifetime US8534291B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/421,444 US8534291B2 (en) 1998-06-10 2006-05-31 Methods of treating inflammation in airways
US13/852,067 US8733367B2 (en) 1998-06-10 2013-03-28 Methods of treating inflammation in airways

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9532398A 1998-06-10 1998-06-10
US09/296,040 US6411852B1 (en) 1997-04-07 1999-04-21 Modification of airways by application of energy
US09/349,715 US6488673B1 (en) 1997-04-07 1999-07-08 Method of increasing gas exchange of a lung
US09/436,455 US7425212B1 (en) 1998-06-10 1999-11-08 Devices for modification of airways by transfer of energy
US09/535,856 US6634363B1 (en) 1997-04-07 2000-03-27 Methods of treating lungs having reversible obstructive pulmonary disease
US10/640,967 US7273055B2 (en) 1998-06-10 2003-08-13 Methods of treating asthma
US11/421,444 US8534291B2 (en) 1998-06-10 2006-05-31 Methods of treating inflammation in airways

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/436,455 Continuation-In-Part US7425212B1 (en) 1997-04-07 1999-11-08 Devices for modification of airways by transfer of energy
US10/640,967 Continuation US7273055B2 (en) 1997-04-07 2003-08-13 Methods of treating asthma

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/296,040 Continuation-In-Part US6411852B1 (en) 1997-04-07 1999-04-21 Modification of airways by application of energy
US13/852,067 Continuation US8733367B2 (en) 1998-06-10 2013-03-28 Methods of treating inflammation in airways

Publications (2)

Publication Number Publication Date
US20060278243A1 true US20060278243A1 (en) 2006-12-14
US8534291B2 US8534291B2 (en) 2013-09-17

Family

ID=27404395

Family Applications (9)

Application Number Title Priority Date Filing Date
US09/535,856 Expired - Lifetime US6634363B1 (en) 1997-04-07 2000-03-27 Methods of treating lungs having reversible obstructive pulmonary disease
US10/640,967 Expired - Fee Related US7273055B2 (en) 1997-04-07 2003-08-13 Methods of treating asthma
US10/809,991 Expired - Fee Related US7264002B2 (en) 1998-06-10 2004-03-26 Methods of treating reversible obstructive pulmonary disease
US11/421,444 Expired - Lifetime US8534291B2 (en) 1998-06-10 2006-05-31 Methods of treating inflammation in airways
US11/421,429 Expired - Fee Related US7542802B2 (en) 1998-06-10 2006-05-31 Methods of regenerating tissue in airways
US11/425,345 Expired - Lifetime US8443810B2 (en) 1998-06-10 2006-06-20 Methods of reducing mucus in airways
US11/614,919 Abandoned US20070118190A1 (en) 1998-06-10 2006-12-21 Methods of treating asthma
US13/852,067 Expired - Fee Related US8733367B2 (en) 1998-06-10 2013-03-28 Methods of treating inflammation in airways
US13/853,588 Abandoned US20130218158A1 (en) 1998-06-10 2013-03-29 Methods of reducing mucus in airways

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US09/535,856 Expired - Lifetime US6634363B1 (en) 1997-04-07 2000-03-27 Methods of treating lungs having reversible obstructive pulmonary disease
US10/640,967 Expired - Fee Related US7273055B2 (en) 1997-04-07 2003-08-13 Methods of treating asthma
US10/809,991 Expired - Fee Related US7264002B2 (en) 1998-06-10 2004-03-26 Methods of treating reversible obstructive pulmonary disease

Family Applications After (5)

Application Number Title Priority Date Filing Date
US11/421,429 Expired - Fee Related US7542802B2 (en) 1998-06-10 2006-05-31 Methods of regenerating tissue in airways
US11/425,345 Expired - Lifetime US8443810B2 (en) 1998-06-10 2006-06-20 Methods of reducing mucus in airways
US11/614,919 Abandoned US20070118190A1 (en) 1998-06-10 2006-12-21 Methods of treating asthma
US13/852,067 Expired - Fee Related US8733367B2 (en) 1998-06-10 2013-03-28 Methods of treating inflammation in airways
US13/853,588 Abandoned US20130218158A1 (en) 1998-06-10 2013-03-29 Methods of reducing mucus in airways

Country Status (9)

Country Link
US (9) US6634363B1 (en)
EP (1) EP1173103B1 (en)
JP (1) JP4243436B2 (en)
AT (1) ATE306859T1 (en)
AU (2) AU777411B2 (en)
CA (1) CA2370223C (en)
DE (1) DE60023283T2 (en)
ES (1) ES2246853T3 (en)
WO (1) WO2000062699A2 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060062808A1 (en) * 2004-09-18 2006-03-23 Asthmatx, Inc. Inactivation of smooth muscle tissue
US7837679B2 (en) 2000-10-17 2010-11-23 Asthmatx, Inc. Control system and process for application of energy to airway walls and other mediums
US7921855B2 (en) 1998-01-07 2011-04-12 Asthmatx, Inc. Method for treating an asthma attack
US7938123B2 (en) 1997-04-07 2011-05-10 Asthmatx, Inc. Modification of airways by application of cryo energy
US7992572B2 (en) 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
US8088127B2 (en) 2008-05-09 2012-01-03 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8172827B2 (en) 2003-05-13 2012-05-08 Innovative Pulmonary Solutions, Inc. Apparatus for treating asthma using neurotoxin
US8181656B2 (en) 1998-06-10 2012-05-22 Asthmatx, Inc. Methods for treating airways
US8251070B2 (en) 2000-03-27 2012-08-28 Asthmatx, Inc. Methods for treating airways
US8257413B2 (en) 2000-10-17 2012-09-04 Asthmatx, Inc. Modification of airways by application of energy
US8443810B2 (en) 1998-06-10 2013-05-21 Asthmatx, Inc. Methods of reducing mucus in airways
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8740895B2 (en) 2009-10-27 2014-06-03 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US9283374B2 (en) 2012-11-05 2016-03-15 Boston Scientific Scimed, Inc. Devices and methods for delivering energy to body lumens
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US9592086B2 (en) 2012-07-24 2017-03-14 Boston Scientific Scimed, Inc. Electrodes for tissue treatment
US9770293B2 (en) 2012-06-04 2017-09-26 Boston Scientific Scimed, Inc. Systems and methods for treating tissue of a passageway within a body
US9950188B2 (en) 2012-05-31 2018-04-24 Color Seven Co., Ltd. Apparatus for relaxing smooth muscles of human body

Families Citing this family (243)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425212B1 (en) * 1998-06-10 2008-09-16 Asthmatx, Inc. Devices for modification of airways by transfer of energy
US6488673B1 (en) * 1997-04-07 2002-12-03 Broncus Technologies, Inc. Method of increasing gas exchange of a lung
US7892229B2 (en) * 2003-01-18 2011-02-22 Tsunami Medtech, Llc Medical instruments and techniques for treating pulmonary disorders
US8016823B2 (en) 2003-01-18 2011-09-13 Tsunami Medtech, Llc Medical instrument and method of use
US20070123958A1 (en) * 1998-06-10 2007-05-31 Asthmatx, Inc. Apparatus for treating airways in the lung
ATE258768T1 (en) * 1999-08-05 2004-02-15 Broncus Tech Inc METHOD AND DEVICES FOR PRODUCING COLLATERAL CHANNELS IN THE LUNGS
US20060095032A1 (en) 1999-11-16 2006-05-04 Jerome Jackson Methods and systems for determining physiologic characteristics for treatment of the esophagus
US6551310B1 (en) 1999-11-16 2003-04-22 Robert A. Ganz System and method of treating abnormal tissue in the human esophagus
US20040215235A1 (en) 1999-11-16 2004-10-28 Barrx, Inc. Methods and systems for determining physiologic characteristics for treatment of the esophagus
US8474460B2 (en) 2000-03-04 2013-07-02 Pulmonx Corporation Implanted bronchial isolation devices and methods
US6527761B1 (en) 2000-10-27 2003-03-04 Pulmonx, Inc. Methods and devices for obstructing and aspirating lung tissue segments
US9433457B2 (en) 2000-12-09 2016-09-06 Tsunami Medtech, Llc Medical instruments and techniques for thermally-mediated therapies
US7549987B2 (en) 2000-12-09 2009-06-23 Tsunami Medtech, Llc Thermotherapy device
US6896692B2 (en) 2000-12-14 2005-05-24 Ensure Medical, Inc. Plug with collet and apparatus and method for delivering such plugs
US8083768B2 (en) 2000-12-14 2011-12-27 Ensure Medical, Inc. Vascular plug having composite construction
US6846319B2 (en) 2000-12-14 2005-01-25 Core Medical, Inc. Devices for sealing openings through tissue and apparatus and methods for delivering them
US6994706B2 (en) 2001-08-13 2006-02-07 Minnesota Medical Physics, Llc Apparatus and method for treatment of benign prostatic hyperplasia
EP1435833B1 (en) 2001-09-10 2014-05-21 Pulmonx Apparatus for endobronchial diagnosis
US7883471B2 (en) 2001-09-10 2011-02-08 Pulmonx Corporation Minimally invasive determination of collateral ventilation in lungs
US20030050648A1 (en) 2001-09-11 2003-03-13 Spiration, Inc. Removable lung reduction devices, systems, and methods
US6592594B2 (en) 2001-10-25 2003-07-15 Spiration, Inc. Bronchial obstruction device deployment system and method
US8444636B2 (en) 2001-12-07 2013-05-21 Tsunami Medtech, Llc Medical instrument and method of use
US6929637B2 (en) 2002-02-21 2005-08-16 Spiration, Inc. Device and method for intra-bronchial provision of a therapeutic agent
US20030216769A1 (en) 2002-05-17 2003-11-20 Dillard David H. Removable anchored lung volume reduction devices and methods
US20030181922A1 (en) 2002-03-20 2003-09-25 Spiration, Inc. Removable anchored lung volume reduction devices and methods
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US20040082859A1 (en) 2002-07-01 2004-04-29 Alan Schaer Method and apparatus employing ultrasound energy to treat body sphincters
DE60323502D1 (en) 2002-07-26 2008-10-23 Emphasys Medical Inc BRONCHIAL FLOW DEVICE WITH A MEMBRANE SEAL
DE602004011608T2 (en) * 2003-03-28 2009-01-29 C.R. Bard, Inc. Catheter with braided mesh
US7100616B2 (en) 2003-04-08 2006-09-05 Spiration, Inc. Bronchoscopic lung volume reduction method
US7811274B2 (en) 2003-05-07 2010-10-12 Portaero, Inc. Method for treating chronic obstructive pulmonary disease
US7426929B2 (en) 2003-05-20 2008-09-23 Portaero, Inc. Intra/extra-thoracic collateral ventilation bypass system and method
US7533667B2 (en) * 2003-05-29 2009-05-19 Portaero, Inc. Methods and devices to assist pulmonary decompression
US7252086B2 (en) 2003-06-03 2007-08-07 Cordis Corporation Lung reduction system
US7377278B2 (en) 2003-06-05 2008-05-27 Portaero, Inc. Intra-thoracic collateral ventilation bypass system and method
US7682332B2 (en) 2003-07-15 2010-03-23 Portaero, Inc. Methods to accelerate wound healing in thoracic anastomosis applications
US8308682B2 (en) 2003-07-18 2012-11-13 Broncus Medical Inc. Devices for maintaining patency of surgically created channels in tissue
US7533671B2 (en) 2003-08-08 2009-05-19 Spiration, Inc. Bronchoscopic repair of air leaks in a lung
US8852229B2 (en) 2003-10-17 2014-10-07 Cordis Corporation Locator and closure device and method of use
US7150745B2 (en) 2004-01-09 2006-12-19 Barrx Medical, Inc. Devices and methods for treatment of luminal tissue
US20050178389A1 (en) * 2004-01-27 2005-08-18 Shaw David P. Disease indications for selective endobronchial lung region isolation
JP4767252B2 (en) 2004-06-14 2011-09-07 ヌームアールエックス・インコーポレーテッド Lung access device
US20050288684A1 (en) * 2004-06-16 2005-12-29 Aronson Nathan A Method of reducing collateral flow in a portion of a lung
US7766891B2 (en) 2004-07-08 2010-08-03 Pneumrx, Inc. Lung device with sealing features
CA2570261C (en) 2004-07-08 2014-06-10 Pneumrx, Inc. Pleural effusion treatment device, method and material
US8409167B2 (en) 2004-07-19 2013-04-02 Broncus Medical Inc Devices for delivering substances through an extra-anatomic opening created in an airway
US20060047291A1 (en) * 2004-08-20 2006-03-02 Uptake Medical Corporation Non-foreign occlusion of an airway and lung collapse
US20060130830A1 (en) * 2004-09-07 2006-06-22 Uptake Medical Corporation Intra-bronchial implants for improved attachment
WO2006052940A2 (en) 2004-11-05 2006-05-18 Asthmatx, Inc. Medical device with procedure improvement features
US7949407B2 (en) 2004-11-05 2011-05-24 Asthmatx, Inc. Energy delivery devices and methods
CA2585150C (en) * 2004-11-12 2014-10-07 Asthmatx, Inc. Improved energy delivery devices and methods
US20070093802A1 (en) 2005-10-21 2007-04-26 Danek Christopher J Energy delivery devices and methods
JP2008519669A (en) * 2004-11-12 2008-06-12 アスマティックス,インコーポレイテッド Apparatus and method for improved energy delivery
CN101115448B (en) 2004-11-16 2010-05-12 罗伯特·L·巴里 Device and method for lung treatment
US9211181B2 (en) 2004-11-19 2015-12-15 Pulmonx Corporation Implant loading device and system
US20060118126A1 (en) * 2004-11-19 2006-06-08 Don Tanaka Methods and devices for controlling collateral ventilation
US8220460B2 (en) 2004-11-19 2012-07-17 Portaero, Inc. Evacuation device and method for creating a localized pleurodesis
US7771472B2 (en) 2004-11-19 2010-08-10 Pulmonx Corporation Bronchial flow control devices and methods of use
US7398782B2 (en) * 2004-11-19 2008-07-15 Portaero, Inc. Method for pulmonary drug delivery
JP4874259B2 (en) 2004-11-23 2012-02-15 ヌームアールエックス・インコーポレーテッド Steerable device for accessing the target site
EP1819304B1 (en) 2004-12-09 2023-01-25 Twelve, Inc. Aortic valve repair
US7824366B2 (en) 2004-12-10 2010-11-02 Portaero, Inc. Collateral ventilation device with chest tube/evacuation features and method
US8496006B2 (en) 2005-01-20 2013-07-30 Pulmonx Corporation Methods and devices for passive residual lung volume reduction and functional lung volume expansion
US20080228137A1 (en) 2007-03-12 2008-09-18 Pulmonx Methods and devices for passive residual lung volume reduction and functional lung volume expansion
US11883029B2 (en) 2005-01-20 2024-01-30 Pulmonx Corporation Methods and devices for passive residual lung volume reduction and functional lung volume expansion
US8308681B2 (en) * 2005-02-09 2012-11-13 Children's Medical Center Corporation Device for mixing and delivering fluids for tissue repair
US8876791B2 (en) 2005-02-25 2014-11-04 Pulmonx Corporation Collateral pathway treatment using agent entrained by aspiration flow current
EP1874211B1 (en) * 2005-04-21 2017-05-31 Boston Scientific Scimed, Inc. Control devices for energy delivery
US8926654B2 (en) 2005-05-04 2015-01-06 Cordis Corporation Locator and closure device and method of use
US8721634B2 (en) 2005-07-21 2014-05-13 Covidien Lp Apparatus and method for ensuring thermal treatment of a hollow anatomical structure
EP2662044B1 (en) * 2005-07-21 2018-10-31 Covidien LP Systems for treating a hollow anatomical structure
EP1906923B1 (en) 2005-07-22 2018-01-24 The Foundry, LLC Systems and methods for delivery of a therapeutic agent
US20070032785A1 (en) 2005-08-03 2007-02-08 Jennifer Diederich Tissue evacuation device
US8104474B2 (en) 2005-08-23 2012-01-31 Portaero, Inc. Collateral ventilation bypass system with retention features
US9037247B2 (en) 2005-11-10 2015-05-19 ElectroCore, LLC Non-invasive treatment of bronchial constriction
US7997278B2 (en) 2005-11-23 2011-08-16 Barrx Medical, Inc. Precision ablating method
US8702694B2 (en) 2005-11-23 2014-04-22 Covidien Lp Auto-aligning ablating device and method of use
US7959627B2 (en) 2005-11-23 2011-06-14 Barrx Medical, Inc. Precision ablating device
GB0523916D0 (en) * 2005-11-24 2006-01-04 Femeda Ltd Compressible electrodes
GB0523918D0 (en) 2005-11-24 2006-01-04 Femeda Ltd Self contained device with treatment cycle for electrostimulation
GB0523917D0 (en) 2005-11-24 2006-01-04 Femeda Ltd Devices for electrostimulation
US8523782B2 (en) 2005-12-07 2013-09-03 Pulmonx Corporation Minimally invasive determination of collateral ventilation in lungs
US7406963B2 (en) * 2006-01-17 2008-08-05 Portaero, Inc. Variable resistance pulmonary ventilation bypass valve and method
US7996059B2 (en) * 2006-03-08 2011-08-09 Biosense Webster, Inc. Esophagus imaging enhancement device
US8888800B2 (en) 2006-03-13 2014-11-18 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US8157837B2 (en) 2006-03-13 2012-04-17 Pneumrx, Inc. Minimally invasive lung volume reduction device and method
US9402633B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Torque alleviating intra-airway lung volume reduction compressive implant structures
US7691151B2 (en) 2006-03-31 2010-04-06 Spiration, Inc. Articulable Anchor
US8652201B2 (en) 2006-04-26 2014-02-18 The Cleveland Clinic Foundation Apparatus and method for treating cardiovascular diseases
US7931647B2 (en) * 2006-10-20 2011-04-26 Asthmatx, Inc. Method of delivering energy to a lung airway using markers
US8585645B2 (en) * 2006-11-13 2013-11-19 Uptake Medical Corp. Treatment with high temperature vapor
US7993323B2 (en) 2006-11-13 2011-08-09 Uptake Medical Corp. High pressure and high temperature vapor catheters and systems
WO2008137757A1 (en) 2007-05-04 2008-11-13 Barrx Medical, Inc. Method and apparatus for gastrointestinal tract ablation for treatment of obesity
US7931641B2 (en) 2007-05-11 2011-04-26 Portaero, Inc. Visceral pleura ring connector
US20080281151A1 (en) * 2007-05-11 2008-11-13 Portaero, Inc. Pulmonary pleural stabilizer
US8163034B2 (en) 2007-05-11 2012-04-24 Portaero, Inc. Methods and devices to create a chemically and/or mechanically localized pleurodesis
US20080283065A1 (en) * 2007-05-15 2008-11-20 Portaero, Inc. Methods and devices to maintain patency of a lumen in parenchymal tissue of the lung
US8062315B2 (en) 2007-05-17 2011-11-22 Portaero, Inc. Variable parietal/visceral pleural coupling
US20080295829A1 (en) * 2007-05-30 2008-12-04 Portaero, Inc. Bridge element for lung implant
EP2152182A4 (en) * 2007-06-04 2011-06-22 Terumo Corp Multi-electrode apparatus for tissue welding and ablation
US8784338B2 (en) 2007-06-22 2014-07-22 Covidien Lp Electrical means to normalize ablational energy transmission to a luminal tissue surface of varying size
WO2009009443A1 (en) 2007-07-06 2009-01-15 Barrx Medical, Inc. Method and apparatus for gastrointestinal tract ablation to achieve loss of persistent and/or recurrent excess body weight following a weight-loss operation
WO2009009398A1 (en) 2007-07-06 2009-01-15 Tsunami Medtech, Llc Medical system and method of use
KR101547931B1 (en) 2007-07-06 2015-08-28 코비디엔 엘피 Ablation in the gastrointestinal tract to achieve hemostasis and eradicate lesions with a propensity for bleeding
US8235983B2 (en) 2007-07-12 2012-08-07 Asthmatx, Inc. Systems and methods for delivering energy to passageways in a patient
WO2009015278A1 (en) * 2007-07-24 2009-01-29 Asthmatx, Inc. System and method for controlling power based on impedance detection, such as controlling power to tissue treatment devices
US8273012B2 (en) 2007-07-30 2012-09-25 Tyco Healthcare Group, Lp Cleaning device and methods
US8646460B2 (en) 2007-07-30 2014-02-11 Covidien Lp Cleaning device and methods
WO2009026528A1 (en) 2007-08-23 2009-02-26 Aegea Medical, Inc. Uterine therapy device and method
CN101868199B (en) 2007-10-12 2016-04-06 斯波瑞申有限公司 valve loader method, system and equipment
US8043301B2 (en) 2007-10-12 2011-10-25 Spiration, Inc. Valve loader method, system, and apparatus
US8322335B2 (en) 2007-10-22 2012-12-04 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
EP2249734B1 (en) * 2007-10-22 2014-03-26 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
US8475389B2 (en) 2008-02-19 2013-07-02 Portaero, Inc. Methods and devices for assessment of pneumostoma function
EP2242527A4 (en) 2008-02-19 2011-07-13 Portaero Inc Devices and methods for delivery of a therapeutic agent through a pneumostoma
US8336540B2 (en) 2008-02-19 2012-12-25 Portaero, Inc. Pneumostoma management device and method for treatment of chronic obstructive pulmonary disease
US9924992B2 (en) 2008-02-20 2018-03-27 Tsunami Medtech, Llc Medical system and method of use
US9833149B2 (en) 2008-03-18 2017-12-05 Circa Scientific, Llc Methods, apparatus and systems for facilitating introduction of shaped medical instruments into the body of a subject
WO2009117523A2 (en) 2008-03-18 2009-09-24 Circa Medical, Llc Large surface area temperature sensing device
US11254926B2 (en) 2008-04-29 2022-02-22 Virginia Tech Intellectual Properties, Inc. Devices and methods for high frequency electroporation
US10702326B2 (en) 2011-07-15 2020-07-07 Virginia Tech Intellectual Properties, Inc. Device and method for electroporation based treatment of stenosis of a tubular body part
AU2009243079A1 (en) 2008-04-29 2009-11-05 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation to create tissue scaffolds
US10245098B2 (en) 2008-04-29 2019-04-02 Virginia Tech Intellectual Properties, Inc. Acute blood-brain barrier disruption using electrical energy based therapy
US10448989B2 (en) 2009-04-09 2019-10-22 Virginia Tech Intellectual Properties, Inc. High-frequency electroporation for cancer therapy
US9867652B2 (en) 2008-04-29 2018-01-16 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
US9198733B2 (en) 2008-04-29 2015-12-01 Virginia Tech Intellectual Properties, Inc. Treatment planning for electroporation-based therapies
US8992517B2 (en) 2008-04-29 2015-03-31 Virginia Tech Intellectual Properties Inc. Irreversible electroporation to treat aberrant cell masses
US10272178B2 (en) 2008-04-29 2019-04-30 Virginia Tech Intellectual Properties Inc. Methods for blood-brain barrier disruption using electrical energy
US9283051B2 (en) 2008-04-29 2016-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
US11272979B2 (en) 2008-04-29 2022-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US10238447B2 (en) 2008-04-29 2019-03-26 Virginia Tech Intellectual Properties, Inc. System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
US10117707B2 (en) 2008-04-29 2018-11-06 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US8721632B2 (en) 2008-09-09 2014-05-13 Tsunami Medtech, Llc Methods for delivering energy into a target tissue of a body
US8579888B2 (en) 2008-06-17 2013-11-12 Tsunami Medtech, Llc Medical probes for the treatment of blood vessels
US9173669B2 (en) 2008-09-12 2015-11-03 Pneumrx, Inc. Enhanced efficacy lung volume reduction devices, methods, and systems
US10695126B2 (en) 2008-10-06 2020-06-30 Santa Anna Tech Llc Catheter with a double balloon structure to generate and apply a heated ablative zone to tissue
US20100094270A1 (en) 2008-10-06 2010-04-15 Sharma Virender K Method and Apparatus for Tissue Ablation
US10064697B2 (en) 2008-10-06 2018-09-04 Santa Anna Tech Llc Vapor based ablation system for treating various indications
US9561068B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US9561066B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US8347881B2 (en) 2009-01-08 2013-01-08 Portaero, Inc. Pneumostoma management device with integrated patency sensor and method
WO2010080886A1 (en) 2009-01-09 2010-07-15 Recor Medical, Inc. Methods and apparatus for treatment of mitral valve in insufficiency
US11284931B2 (en) 2009-02-03 2022-03-29 Tsunami Medtech, Llc Medical systems and methods for ablating and absorbing tissue
US8518053B2 (en) 2009-02-11 2013-08-27 Portaero, Inc. Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease
US8632534B2 (en) * 2009-04-03 2014-01-21 Angiodynamics, Inc. Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD)
US11638603B2 (en) 2009-04-09 2023-05-02 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US11382681B2 (en) 2009-04-09 2022-07-12 Virginia Tech Intellectual Properties, Inc. Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
JP5809621B2 (en) 2009-05-18 2015-11-11 ヌームアールエックス・インコーポレーテッド Implants for treating a patient's lungs
US8903488B2 (en) 2009-05-28 2014-12-02 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
US8900223B2 (en) 2009-11-06 2014-12-02 Tsunami Medtech, Llc Tissue ablation systems and methods of use
US9161801B2 (en) 2009-12-30 2015-10-20 Tsunami Medtech, Llc Medical system and method of use
US9107606B2 (en) 2010-01-08 2015-08-18 Pulmonx Corporation Measuring lung function and lung disease progression at a lobar/segmental level
EP2563256B1 (en) 2010-04-26 2019-08-28 Medtronic Holding Company Sàrl Electrosurgical device
US9744339B2 (en) 2010-05-12 2017-08-29 Circa Scientific, Llc Apparatus for manually manipulating hollow organs
RU2454088C2 (en) * 2010-07-09 2012-06-27 Федеральное государственное учреждение "Томский научно-исследовательский институт курортологии и физиотерапии Федерального медико-биологического агентства России" (ФГУ ТНИИКиФ ФМБА России) Method of rehabilitation of patients with bronchial asthma with accompanying allergic rhinitis
US9943353B2 (en) 2013-03-15 2018-04-17 Tsunami Medtech, Llc Medical system and method of use
US9743974B2 (en) 2010-11-09 2017-08-29 Aegea Medical Inc. Positioning method and apparatus for delivering vapor to the uterus
US10278774B2 (en) 2011-03-18 2019-05-07 Covidien Lp Selectively expandable operative element support structure and methods of use
US8795241B2 (en) 2011-05-13 2014-08-05 Spiration, Inc. Deployment catheter
US9345532B2 (en) 2011-05-13 2016-05-24 Broncus Medical Inc. Methods and devices for ablation of tissue
US8709034B2 (en) 2011-05-13 2014-04-29 Broncus Medical Inc. Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
US11304746B2 (en) 2011-06-14 2022-04-19 Aerin Medical Inc. Method of treating airway tissue to reduce mucus secretion
CN103747754B (en) 2011-06-14 2016-07-06 艾琳医药股份有限公司 For treating the device of nose air flue
US10456185B2 (en) 2011-06-14 2019-10-29 Aerin Medical, Inc. Methods and devices to treat nasal airways
US10722282B2 (en) 2011-06-14 2020-07-28 Aerin Medical, Inc. Methods and devices to treat nasal airways
US11241271B2 (en) 2011-06-14 2022-02-08 Aerin Medical Inc. Methods of treating nasal airways
US11033318B2 (en) 2011-06-14 2021-06-15 Aerin Medical, Inc. Methods and devices to treat nasal airways
US9415194B2 (en) 2011-06-14 2016-08-16 Aerin Medical Inc. Post nasal drip treatment
US9078665B2 (en) 2011-09-28 2015-07-14 Angiodynamics, Inc. Multiple treatment zone ablation probe
WO2013052501A1 (en) 2011-10-05 2013-04-11 Innovative Pulmonary Solutions, Inc. Apparatus for injuring nerve tissue
JP6017568B2 (en) 2011-10-07 2016-11-02 イージー メディカル, インコーポレーテッド Uterine treatment device
WO2013078235A1 (en) 2011-11-23 2013-05-30 Broncus Medical Inc Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
WO2013176100A1 (en) * 2012-05-23 2013-11-28 テルモ株式会社 Tissue separation device
WO2014020666A1 (en) * 2012-07-30 2014-02-06 テルモ株式会社 Medical heat-treatment tool
EP2892612B8 (en) 2012-09-05 2021-03-24 electroCore, Inc. Device for non-invasive vagal nerve stimulation to treat disorders
US9272132B2 (en) 2012-11-02 2016-03-01 Boston Scientific Scimed, Inc. Medical device for treating airways and related methods of use
GB201221123D0 (en) * 2012-11-23 2013-01-09 Photocure As Device for photodynamic treatment
JP6059737B2 (en) * 2012-11-30 2017-01-11 株式会社グッドマン Ablation catheter
EP2945556A4 (en) 2013-01-17 2016-08-31 Virender K Sharma Method and apparatus for tissue ablation
KR101390672B1 (en) 2013-01-24 2014-04-30 부경대학교 산학협력단 Bronchial optical diffuser for acute asthma treatment
ITTO20130062A1 (en) * 2013-01-25 2014-07-26 Alessio Biglia VASCULAR DILATOR
CA2896787A1 (en) * 2013-02-05 2014-08-14 Handok Inc. Catheter for denervation
CN104994783B (en) 2013-02-08 2018-11-13 柯惠有限合伙公司 System and method for nervus pulmonalis resection
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
EP2967397B1 (en) 2013-03-15 2023-07-12 Medtronic Holding Company Sàrl Electrosurgical mapping tools
US9814618B2 (en) * 2013-06-06 2017-11-14 Boston Scientific Scimed, Inc. Devices for delivering energy and related methods of use
CN105451680B (en) 2013-08-09 2019-10-08 波士顿科学国际有限公司 The correlation technique of expansible conduit and manufacture and use
US10603059B2 (en) 2013-09-13 2020-03-31 Aerin Medical Inc. Hyaline cartilage shaping
US9687288B2 (en) 2013-09-30 2017-06-27 Arrinex, Inc. Apparatus and methods for treating rhinitis
US9782211B2 (en) 2013-10-01 2017-10-10 Uptake Medical Technology Inc. Preferential volume reduction of diseased segments of a heterogeneous lobe
JP2015077301A (en) * 2013-10-17 2015-04-23 オリンパス株式会社 Method for manufacturing treatment instrument and treatment instrument
EP3057521B1 (en) 2013-10-18 2020-03-25 Boston Scientific Scimed, Inc. Balloon catheters with flexible conducting wires
EP3071134A1 (en) 2013-11-19 2016-09-28 Ethicon, Inc. Thoracoscopic methods for treatment of bronchial disease
US9579149B2 (en) 2014-03-13 2017-02-28 Medtronic Ardian Luxembourg S.A.R.L. Low profile catheter assemblies and associated systems and methods
WO2015143357A2 (en) 2014-03-21 2015-09-24 Boston Scientific Scimed, Inc. Devices and methods for treating a lung
US20150270634A1 (en) * 2014-03-21 2015-09-24 St. Jude Medical, Cardiology Division, Inc. Electrode assembly for catheter system including struts having a non-uniform thickness
AU2015259303B2 (en) 2014-05-12 2021-10-28 Arena, Christopher B. Selective modulation of intracellular effects of cells using pulsed electric fields
CN106794030B (en) 2014-05-22 2019-09-03 埃杰亚医疗公司 System and method for executing endometrial ablation
CN106794031B (en) 2014-05-22 2020-03-10 埃杰亚医疗公司 Integrity testing method and apparatus for delivering vapor to uterus
US9763743B2 (en) 2014-07-25 2017-09-19 Arrinex, Inc. Apparatus and method for treating rhinitis
GB201414695D0 (en) 2014-08-19 2014-10-01 Femeda Ltd Electrostimulation related devices and methods
US10390838B1 (en) 2014-08-20 2019-08-27 Pneumrx, Inc. Tuned strength chronic obstructive pulmonary disease treatment
US10485604B2 (en) 2014-12-02 2019-11-26 Uptake Medical Technology Inc. Vapor treatment of lung nodules and tumors
WO2016100325A1 (en) 2014-12-15 2016-06-23 Virginia Tech Intellectual Properties, Inc. Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
US10531906B2 (en) 2015-02-02 2020-01-14 Uptake Medical Technology Inc. Medical vapor generator
EP3254617B1 (en) * 2015-02-03 2021-03-17 National University Corporation Nagoya University Heartbeat signal detecting device and airway flow rate measuring device used for same
US10105531B2 (en) 2015-09-07 2018-10-23 Femeda Ltd. Device for electrostimulation
US10441339B2 (en) 2015-11-17 2019-10-15 Medtronic Holding Company Sárl Spinal tissue ablation apparatus, system, and method
KR20180094955A (en) * 2015-12-15 2018-08-24 에이전시 포 사이언스, 테크놀로지 앤드 리서치 Deployable multi-spinal device and method for catheter-based kidney nerve block
KR101644072B1 (en) * 2016-01-21 2016-08-01 부경대학교 산학협력단 Apparatus for translumenal circumferential energy delivery
EP3416551B1 (en) 2016-02-19 2022-10-12 Aegea Medical Inc. Apparatus for determining the integrity of a bodily cavity
US10864035B2 (en) 2016-03-04 2020-12-15 Aerin Medical, Inc. Eustachian tube modification
US11331140B2 (en) 2016-05-19 2022-05-17 Aqua Heart, Inc. Heated vapor ablation systems and methods for treating cardiac conditions
AU2017289267B2 (en) 2016-06-27 2021-08-12 Galvanize Therapeutics, Inc. Generator and a catheter with an electrode and a method for treating a lung passageway
JP6671077B2 (en) * 2016-11-10 2020-03-25 日本ライフライン株式会社 Electrode catheter for lung cancer treatment
US10905492B2 (en) 2016-11-17 2021-02-02 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
US11806071B2 (en) 2016-12-22 2023-11-07 Aerin Medical Inc. Soft palate treatment
US11116566B2 (en) 2016-12-22 2021-09-14 Aerin Medical, Inc. Soft palate treatment
EP3606457A4 (en) 2017-04-03 2021-04-21 Broncus Medical Inc. Electrosurgical access sheath
US11278356B2 (en) 2017-04-28 2022-03-22 Arrinex, Inc. Systems and methods for locating blood vessels in the treatment of rhinitis
USD880694S1 (en) 2017-05-01 2020-04-07 Aerin Medical, Inc. Nasal airway medical instrument
US11129673B2 (en) 2017-05-05 2021-09-28 Uptake Medical Technology Inc. Extra-airway vapor ablation for treating airway constriction in patients with asthma and COPD
US11096738B2 (en) 2017-05-05 2021-08-24 Aerin Medical, Inc. Treatment of spinal tissue
US11344364B2 (en) 2017-09-07 2022-05-31 Uptake Medical Technology Inc. Screening method for a target nerve to ablate for the treatment of inflammatory lung disease
US11350988B2 (en) 2017-09-11 2022-06-07 Uptake Medical Technology Inc. Bronchoscopic multimodality lung tumor treatment
USD845467S1 (en) 2017-09-17 2019-04-09 Uptake Medical Technology Inc. Hand-piece for medical ablation catheter
US11419658B2 (en) 2017-11-06 2022-08-23 Uptake Medical Technology Inc. Method for treating emphysema with condensable thermal vapor
US11607537B2 (en) 2017-12-05 2023-03-21 Virginia Tech Intellectual Properties, Inc. Method for treating neurological disorders, including tumors, with electroporation
US11490946B2 (en) 2017-12-13 2022-11-08 Uptake Medical Technology Inc. Vapor ablation handpiece
US11311329B2 (en) 2018-03-13 2022-04-26 Virginia Tech Intellectual Properties, Inc. Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
CN110313984B (en) * 2018-03-30 2022-03-29 上海微创电生理医疗科技股份有限公司 Ablation catheter and ablation system
WO2019232432A1 (en) 2018-06-01 2019-12-05 Santa Anna Tech Llc Multi-stage vapor-based ablation treatment methods and vapor generation and delivery systems
WO2020028286A1 (en) * 2018-08-02 2020-02-06 Boston Scientific Scimed, Inc. Devices and methods for treatment of body lumens
USD902412S1 (en) 2018-10-31 2020-11-17 Aerin Medical, Inc. Electrosurgery console
USD881904S1 (en) 2018-10-31 2020-04-21 Aerin Medical Inc. Display screen with animated graphical user interface
CN111227929A (en) * 2018-11-29 2020-06-05 上海安臻医疗科技有限公司 Adjustable bronchus thermoforming pipe
US11653927B2 (en) 2019-02-18 2023-05-23 Uptake Medical Technology Inc. Vapor ablation treatment of obstructive lung disease
KR102198014B1 (en) * 2020-04-23 2021-01-08 비손메디칼 주식회사 Endo tube and system capable of trachea treatment
KR102213647B1 (en) * 2020-06-19 2021-02-10 비손메디칼 주식회사 Endo tracheal tube capable of treating trachea and trachea treatment system using the endo tracheal tube
WO2022162889A1 (en) * 2021-01-29 2022-08-04 日本ライフライン株式会社 Catheter
CN113599715A (en) * 2021-09-02 2021-11-05 北京翌光医疗科技研究院有限公司 Optical medical device

Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1216183A (en) * 1916-09-18 1917-02-13 Charles M Swingle Electrotherapeutic rejuvenator.
US2072346A (en) * 1934-10-04 1937-03-02 Ward R Smith Drainage tube
US3568659A (en) * 1968-09-24 1971-03-09 James N Karnegis Disposable percutaneous intracardiac pump and method of pumping blood
US4502490A (en) * 1980-10-28 1985-03-05 Antec Systems Limited Patient monitoring equipment, probe for use therewith, and method of measuring anesthesia based on oesophagal contractions
US4503855A (en) * 1981-12-31 1985-03-12 Harald Maslanka High frequency surgical snare electrode
US4565200A (en) * 1980-09-24 1986-01-21 Cosman Eric R Universal lesion and recording electrode system
US4567882A (en) * 1982-12-06 1986-02-04 Vanderbilt University Method for locating the illuminated tip of an endotracheal tube
US4643186A (en) * 1985-10-30 1987-02-17 Rca Corporation Percutaneous transluminal microwave catheter angioplasty
US4646737A (en) * 1983-06-13 1987-03-03 Laserscope, Inc. Localized heat applying medical device
US4799479A (en) * 1984-10-24 1989-01-24 The Beth Israel Hospital Association Method and apparatus for angioplasty
US4802492A (en) * 1987-03-11 1989-02-07 National Jewish Center For Immunology And Respiratory Medicine Method for determining respiratory function
US4895557A (en) * 1987-12-07 1990-01-23 Nimbus Medical, Inc. Drive mechanism for powering intravascular blood pumps
US4906229A (en) * 1988-05-03 1990-03-06 Nimbus Medical, Inc. High-frequency transvalvular axisymmetric blood pump
US4908012A (en) * 1988-08-08 1990-03-13 Nimbus Medical, Inc. Chronic ventricular assist system
US4907589A (en) * 1988-04-29 1990-03-13 Cosman Eric R Automatic over-temperature control apparatus for a therapeutic heating device
US4985014A (en) * 1989-07-11 1991-01-15 Orejola Wilmo C Ventricular venting loop
US4991603A (en) * 1989-10-30 1991-02-12 Siemens-Pacesetter, Inc. Transvenously placed defibrillation leads via an inferior vena cava access site and method of use
US5078716A (en) * 1990-05-11 1992-01-07 Doll Larry F Electrosurgical apparatus for resecting abnormal protruding growth
US5084044A (en) * 1989-07-14 1992-01-28 Ciron Corporation Apparatus for endometrial ablation and method of using same
US5096916A (en) * 1990-05-07 1992-03-17 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
US5100423A (en) * 1990-08-21 1992-03-31 Medical Engineering & Development Institute, Inc. Ablation catheter
US5100388A (en) * 1989-09-15 1992-03-31 Interventional Thermodynamics, Inc. Method and device for thermal ablation of hollow body organs
US5188602A (en) * 1990-07-12 1993-02-23 Interventional Thermodynamics, Inc. Method and device for delivering heat to hollow body organs
US5191883A (en) * 1988-10-28 1993-03-09 Prutech Research And Development Partnership Ii Device for heating tissue in a patient's body
US5281218A (en) * 1992-06-05 1994-01-25 Cardiac Pathways Corporation Catheter having needle electrode for radiofrequency ablation
US5292331A (en) * 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5293869A (en) * 1992-09-25 1994-03-15 Ep Technologies, Inc. Cardiac probe with dynamic support for maintaining constant surface contact during heart systole and diastole
US5383917A (en) * 1991-07-05 1995-01-24 Jawahar M. Desai Device and method for multi-phase radio-frequency ablation
US5393207A (en) * 1993-01-21 1995-02-28 Nimbus, Inc. Blood pump with disposable rotor assembly
US5394880A (en) * 1994-03-17 1995-03-07 Atlee, Iii; John L. Esophageal stethoscope
US5396887A (en) * 1993-09-23 1995-03-14 Cardiac Pathways Corporation Apparatus and method for detecting contact pressure
US5400778A (en) * 1990-06-18 1995-03-28 Siemens-Elema Ab Method and device for reduction of rebreathing of gas from dead space
US5400783A (en) * 1993-10-12 1995-03-28 Cardiac Pathways Corporation Endocardial mapping apparatus with rotatable arm and method
US5496312A (en) * 1993-10-07 1996-03-05 Valleylab Inc. Impedance and temperature generator control
US5496311A (en) * 1988-10-28 1996-03-05 Boston Scientific Corporation Physiologic low stress angioplasty
US5496271A (en) * 1990-09-14 1996-03-05 American Medical Systems, Inc. Combined hyperthermia and dilation catheter
US5500011A (en) * 1986-11-14 1996-03-19 Desai; Jawahar M. Catheter for mapping and ablation and method therefor
US5595183A (en) * 1995-02-17 1997-01-21 Ep Technologies, Inc. Systems and methods for examining heart tissue employing multiple electrode structures and roving electrodes
US5598848A (en) * 1994-03-31 1997-02-04 Ep Technologies, Inc. Systems and methods for positioning multiple electrode structures in electrical contact with the myocardium
US5599345A (en) * 1993-11-08 1997-02-04 Zomed International, Inc. RF treatment apparatus
US5601088A (en) * 1995-02-17 1997-02-11 Ep Technologies, Inc. Systems and methods for filtering artifacts from composite signals
US5605157A (en) * 1995-02-17 1997-02-25 Ep Technologies, Inc. Systems and methods for filtering signals derived from biological events
US5607419A (en) * 1995-04-24 1997-03-04 Angiomedics Ii Inc. Method and apparatus for treating vessel wall with UV radiation following angioplasty
US5607462A (en) * 1993-09-24 1997-03-04 Cardiac Pathways Corporation Catheter assembly, catheter and multi-catheter introducer for use therewith
US5707336A (en) * 1995-01-09 1998-01-13 Cardassist Incorporated Ventricular assist device
US5707218A (en) * 1995-04-19 1998-01-13 Nimbus, Inc. Implantable electric axial-flow blood pump with blood cooled bearing
US5707352A (en) * 1989-08-28 1998-01-13 Alliance Pharmaceutical Corp. Pulmonary delivery of therapeutic agent
US5722403A (en) * 1996-10-28 1998-03-03 Ep Technologies, Inc. Systems and methods using a porous electrode for ablating and visualizing interior tissue regions
US5722401A (en) * 1994-10-19 1998-03-03 Cardiac Pathways Corporation Endocardial mapping and/or ablation catheter probe
US5722416A (en) * 1995-02-17 1998-03-03 Ep Technologies, Inc. Systems and methods for analyzing biopotential morphologies in heart tissue to locate potential ablation sites
US5725525A (en) * 1993-03-16 1998-03-10 Ep Technologies, Inc. Multiple electrode support structures with integral hub and spline elements
US5727569A (en) * 1996-02-20 1998-03-17 Cardiothoracic Systems, Inc. Surgical devices for imposing a negative pressure to fix the position of cardiac tissue during surgery
US5728094A (en) * 1996-02-23 1998-03-17 Somnus Medical Technologies, Inc. Method and apparatus for treatment of air way obstructions
US5730704A (en) * 1992-02-24 1998-03-24 Avitall; Boaz Loop electrode array mapping and ablation catheter for cardiac chambers
US5730726A (en) * 1996-03-04 1998-03-24 Klingenstein; Ralph James Apparatus and method for removing fecal impaction
US5730741A (en) * 1997-02-07 1998-03-24 Eclipse Surgical Technologies, Inc. Guided spiral catheter
US5855577A (en) * 1996-09-17 1999-01-05 Eclipse Surgical Technologies, Inc. Bow shaped catheter
US5860974A (en) * 1993-07-01 1999-01-19 Boston Scientific Corporation Heart ablation catheter with expandable electrode and method of coupling energy to an electrode on a catheter shaft
US5863291A (en) * 1996-04-08 1999-01-26 Cardima, Inc. Linear ablation assembly
US5865791A (en) * 1995-06-07 1999-02-02 E.P. Technologies Inc. Atrial appendage stasis reduction procedure and devices
US5868740A (en) * 1995-03-24 1999-02-09 Board Of Regents-Univ Of Nebraska Method for volumetric tissue ablation
US5871523A (en) * 1993-10-15 1999-02-16 Ep Technologies, Inc. Helically wound radio-frequency emitting electrodes for creating lesions in body tissue
US5871443A (en) * 1992-09-25 1999-02-16 Ep Technologies, Inc. Cardiac mapping and ablation systems
US5873865A (en) * 1997-02-07 1999-02-23 Eclipse Surgical Technologies, Inc. Spiral catheter with multiple guide holes
US5873852A (en) * 1995-07-10 1999-02-23 Interventional Technologies Device for injecting fluid into a wall of a blood vessel
US5876399A (en) * 1997-05-28 1999-03-02 Irvine Biomedical, Inc. Catheter system and methods thereof
US5876340A (en) * 1997-04-17 1999-03-02 Irvine Biomedical, Inc. Ablation apparatus with ultrasonic imaging capabilities
US5882346A (en) * 1996-07-15 1999-03-16 Cardiac Pathways Corporation Shapable catheter using exchangeable core and method of use
US5881727A (en) * 1993-10-14 1999-03-16 Ep Technologies, Inc. Integrated cardiac mapping and ablation probe
US6009877A (en) * 1994-06-24 2000-01-04 Edwards; Stuart D. Method for treating a sphincter
US6010500A (en) * 1997-07-21 2000-01-04 Cardiac Pathways Corporation Telescoping apparatus and method for linear lesion ablation
US6014579A (en) * 1997-07-21 2000-01-11 Cardiac Pathways Corp. Endocardial mapping catheter with movable electrode
US6016437A (en) * 1996-10-21 2000-01-18 Irvine Biomedical, Inc. Catheter probe system with inflatable soft shafts
US6023638A (en) * 1995-07-28 2000-02-08 Scimed Life Systems, Inc. System and method for conducting electrophysiological testing using high-voltage energy pulses to stun tissue
US6024740A (en) * 1997-07-08 2000-02-15 The Regents Of The University Of California Circumferential ablation device assembly
US6029091A (en) * 1998-07-09 2000-02-22 Irvine Biomedical, Inc. Catheter system having lattice electrodes
US6033397A (en) * 1996-03-05 2000-03-07 Vnus Medical Technologies, Inc. Method and apparatus for treating esophageal varices
US6036689A (en) * 1998-09-24 2000-03-14 Tu; Lily Chen Ablation device for treating atherosclerotic tissues
US6036687A (en) * 1996-03-05 2000-03-14 Vnus Medical Technologies, Inc. Method and apparatus for treating venous insufficiency
US6039731A (en) * 1995-06-09 2000-03-21 Engineering & Research Associates, Inc. Apparatus and method for determining the extent of ablation
US6179833B1 (en) * 1995-06-09 2001-01-30 Engineering & Research Associates, Inc. Apparatus for thermal ablation
US6183468B1 (en) * 1998-09-10 2001-02-06 Scimed Life Systems, Inc. Systems and methods for controlling power in an electrosurgical probe
US6338836B1 (en) * 1999-09-28 2002-01-15 Siemens Aktiengesellschaft Asthma analysis method employing hyperpolarized gas and magnetic resonance imaging
US6338727B1 (en) * 1998-08-13 2002-01-15 Alsius Corporation Indwelling heat exchange catheter and method of using same
US6346104B2 (en) * 1996-04-30 2002-02-12 Western Sydney Area Health Service System for simultaneous unipolar multi-electrode ablation
US6514246B1 (en) * 1993-10-14 2003-02-04 Ep Technologies, Inc. Systems and methods for forming large lesions in body tissue using curvilinear electrode elements
US6526320B2 (en) * 1998-11-16 2003-02-25 United States Surgical Corporation Apparatus for thermal treatment of tissue
US6673068B1 (en) * 2000-04-12 2004-01-06 Afx, Inc. Electrode arrangement for use in a medical instrument
US6692492B2 (en) * 2001-11-28 2004-02-17 Cardiac Pacemaker, Inc. Dielectric-coated ablation electrode having a non-coated window with thermal sensors
US6837888B2 (en) * 1995-06-07 2005-01-04 Arthrocare Corporation Electrosurgical probe with movable return electrode and methods related thereto
US6840243B2 (en) * 2000-03-04 2005-01-11 Emphasys Medical, Inc. Methods and devices for use in performing pulmonary procedures
US6849073B2 (en) * 1998-07-07 2005-02-01 Medtronic, Inc. Apparatus and method for creating, maintaining, and controlling a virtual electrode used for the ablation of tissue
US6852110B2 (en) * 2002-08-01 2005-02-08 Solarant Medical, Inc. Needle deployment for temperature sensing from an electrode
US6852091B2 (en) * 1992-08-12 2005-02-08 Medtronic Vidamed, Inc. Medical probe device and method
US20080004596A1 (en) * 2006-05-25 2008-01-03 Palo Alto Institute Delivery of agents by microneedle catheter
US20090018538A1 (en) * 2007-07-12 2009-01-15 Asthmatx, Inc. Systems and methods for delivering energy to passageways in a patient
US20090030477A1 (en) * 2007-07-24 2009-01-29 Asthmatx, Inc. System and method for controlling power based on impedance detection, such as controlling power to tissue treatment devices
US20090043301A1 (en) * 2007-08-09 2009-02-12 Asthmatx, Inc. Monopolar energy delivery devices and methods for controlling current density in tissue
US7992572B2 (en) * 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
US8251070B2 (en) * 2000-03-27 2012-08-28 Asthmatx, Inc. Methods for treating airways

Family Cites Families (381)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US612724A (en) 1898-10-18 Bert j
US1155169A (en) 1914-11-28 1915-09-28 John Starkweather Surgical instrument.
US1207479A (en) 1915-03-05 1916-12-05 Holger Bisgaard Self-retaining gatheter.
US3320957A (en) 1964-05-21 1967-05-23 Sokolik Edward Surgical instrument
US3667476A (en) 1970-04-27 1972-06-06 Bio Data Corp Apparatus for monitoring body temperature and controlling a heating device to maintain a selected temperature
US3692029A (en) 1971-05-03 1972-09-19 Edwin Lloyd Adair Retention catheter and suprapubic shunt
US3995617A (en) 1972-05-31 1976-12-07 Watkins David H Heart assist method and catheter
SU545358A1 (en) 1974-07-11 1977-02-05 Предприятие П/Я В-2481 Circulatory Support Device
US4095602A (en) 1976-09-27 1978-06-20 Leveen Harry H Multi-portal radiofrequency generator
US4129129A (en) 1977-03-18 1978-12-12 Sarns, Inc. Venous return catheter and a method of using the same
US4116589A (en) 1977-04-15 1978-09-26 Avco Corporation Extracorporeal pulsatile blood pump comprised of side by side bladders
US4154246A (en) * 1977-07-25 1979-05-15 Leveen Harry H Field intensification in radio frequency thermotherapy
US4557272A (en) 1980-03-31 1985-12-10 Microwave Associates, Inc. Microwave endoscope detection and treatment system
JPS57168656A (en) 1981-04-10 1982-10-18 Medos Kenkyusho Kk Endoscope laser coagulator
US4706688A (en) 1981-05-18 1987-11-17 Don Michael T Anthony Non-invasive cardiac device
US4612934A (en) 1981-06-30 1986-09-23 Borkan William N Non-invasive multiprogrammable tissue stimulator
US4584998A (en) 1981-09-11 1986-04-29 Mallinckrodt, Inc. Multi-purpose tracheal tube
JPS5883966A (en) 1981-11-13 1983-05-19 テルモ株式会社 Blood circuit for membrane type artificial lung
US4512762A (en) 1982-11-23 1985-04-23 The Beth Israel Hospital Association Method of treatment of atherosclerosis and a balloon catheter for same
US4773899A (en) 1982-11-23 1988-09-27 The Beth Israel Hospital Association Method of treatment of artherosclerosis and balloon catheter the same
US4784135A (en) 1982-12-09 1988-11-15 International Business Machines Corporation Far ultraviolet surgical and dental procedures
GB8323390D0 (en) * 1983-08-31 1983-10-05 Ici Plc Production of cathode
US4704121A (en) 1983-09-28 1987-11-03 Nimbus, Inc. Anti-thrombogenic blood pump
US4625712A (en) 1983-09-28 1986-12-02 Nimbus, Inc. High-capacity intravascular blood pump utilizing percutaneous access
US4522212A (en) 1983-11-14 1985-06-11 Mansfield Scientific, Inc. Endocardial electrode
FR2561929B1 (en) 1984-03-27 1989-02-03 Atesys IMPLANTED AUTOMATIC APPARATUS FOR VENTRICULAR DEFIBRILLATION
US4621882A (en) 1984-05-14 1986-11-11 Beta Phase, Inc. Thermally responsive electrical connector
JPS6148350A (en) 1984-08-15 1986-03-10 オリンパス光学工業株式会社 Medical laser apparatus
US5019075A (en) 1984-10-24 1991-05-28 The Beth Israel Hospital Method and apparatus for angioplasty
US4772112A (en) 1984-11-30 1988-09-20 Cvi/Beta Ventures, Inc. Eyeglass frame including shape-memory elements
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
GB2171309B (en) 1985-02-26 1988-11-02 North China Res I Electro Opti Microwave therapeutic apparatus
US4739759A (en) 1985-02-26 1988-04-26 Concept, Inc. Microprocessor controlled electrosurgical generator
US4862886A (en) 1985-05-08 1989-09-05 Summit Technology Inc. Laser angioplasty
US4976709A (en) 1988-12-15 1990-12-11 Sand Bruce J Method for collagen treatment
US4683890A (en) 1985-12-23 1987-08-04 Brunswick Manufacturing Co., Inc. Method and apparatus for controlled breathing employing internal and external electrodes
US4827935A (en) 1986-04-24 1989-05-09 Purdue Research Foundation Demand electroventilator
US4709698A (en) 1986-05-14 1987-12-01 Thomas J. Fogarty Heatable dilation catheter
US4790305A (en) * 1986-06-23 1988-12-13 The Johns Hopkins University Medication delivery system
US4754752A (en) 1986-07-28 1988-07-05 Robert Ginsburg Vascular catheter
US5215103A (en) 1986-11-14 1993-06-01 Desai Jawahar M Catheter for mapping and ablation and method therefor
US5027829A (en) 1986-12-15 1991-07-02 Larsen Lawrence E Apparatus for diathermy treatment and control
GB8704104D0 (en) * 1987-02-21 1987-03-25 Manitoba University Of Respiratory system load apparatus
US4779614A (en) 1987-04-09 1988-10-25 Nimbus Medical, Inc. Magnetically suspended rotor axial flow blood pump
US5849026A (en) 1987-05-20 1998-12-15 Zhou; Lin Physiotherapy method
JPS6446056U (en) 1987-09-17 1989-03-22
US4817586A (en) 1987-11-24 1989-04-04 Nimbus Medical, Inc. Percutaneous bloom pump with mixed-flow output
US4846152A (en) 1987-11-24 1989-07-11 Nimbus Medical, Inc. Single-stage axial flow blood pump
US5588432A (en) 1988-03-21 1996-12-31 Boston Scientific Corporation Catheters for imaging, sensing electrical potentials, and ablating tissue
US5010892A (en) 1988-05-04 1991-04-30 Triangle Research And Development Corp. Body lumen measuring instrument
AU3696989A (en) * 1988-05-18 1989-12-12 Kasevich Associates, Inc. Microwave balloon angioplasty
DE3821544C2 (en) 1988-06-25 1994-04-28 H Prof Dr Med Just Dilatation catheter
US4967765A (en) 1988-07-28 1990-11-06 Bsd Medical Corporation Urethral inserted applicator for prostate hyperthermia
US4920978A (en) 1988-08-31 1990-05-01 Triangle Research And Development Corporation Method and apparatus for the endoscopic treatment of deep tumors using RF hyperthermia
JP2686982B2 (en) 1988-09-02 1997-12-08 日産自動車株式会社 Method for forming clear coating film
US4955377A (en) 1988-10-28 1990-09-11 Lennox Charles D Device and method for heating tissue in a patient's body
US4945912A (en) 1988-11-25 1990-08-07 Sensor Electronics, Inc. Catheter with radiofrequency heating applicator
US4969865A (en) 1989-01-09 1990-11-13 American Biomed, Inc. Helifoil pump
US5779698A (en) 1989-01-18 1998-07-14 Applied Medical Resources Corporation Angioplasty catheter system and method for making same
US4944722A (en) 1989-02-23 1990-07-31 Nimbus Medical, Inc. Percutaneous axial flow blood pump
US5433730A (en) 1989-05-03 1995-07-18 Intermedics, Inc. Conductive pouch electrode for defibrillation
US5152286A (en) 1989-05-08 1992-10-06 Mezhotraslevoi Nauchnoinzhenerny Tsentr "Vidguk" Method of microwave resonance therapy and device therefor
US5114423A (en) 1989-05-15 1992-05-19 Advanced Cardiovascular Systems, Inc. Dilatation catheter assembly with heated balloon
US5074860A (en) 1989-06-09 1991-12-24 Heraeus Lasersonics, Inc. Apparatus for directing 10.6 micron laser radiation to a tissue site
DE3920862A1 (en) 1989-06-26 1991-01-03 Teves Gmbh Alfred AUXILIARY STEERING FOR MOTOR VEHICLES
US5057105A (en) 1989-08-28 1991-10-15 The University Of Kansas Med Center Hot tip catheter assembly
WO1991003267A1 (en) * 1989-08-28 1991-03-21 Sekins K Michael Lung cancer hyperthermia via ultrasound and/or convection with perfluorocarbon liquids
US5167223A (en) 1989-09-08 1992-12-01 Tibor Koros Heart valve retractor and sternum spreader surgical instrument
US5117828A (en) 1989-09-25 1992-06-02 Arzco Medical Electronics, Inc. Expandable esophageal catheter
US5036848A (en) 1989-10-16 1991-08-06 Brunswick Biomedical Technologies, Inc. Method and apparatus for controlling breathing employing internal and external electrodes
US5203832A (en) 1989-11-17 1993-04-20 Long Manufacturing Ltd. Circumferential flow heat exchanger
US5009636A (en) 1989-12-06 1991-04-23 The Kendall Company Dual-lumen catheter apparatus and method
US5254088A (en) 1990-02-02 1993-10-19 Ep Technologies, Inc. Catheter steering mechanism
ATE120377T1 (en) 1990-02-08 1995-04-15 Howmedica INFLATABLE DILATATOR.
FR2659240B1 (en) 1990-03-06 1997-07-04 Daniel Galley EPIDURAL ELECTRODE SYSTEM CALLED TO BE INTRODUCED INTO THE EPIDURAL SPACE.
US5549559A (en) 1990-03-22 1996-08-27 Argomed Ltd. Thermal treatment apparatus
US5236413B1 (en) 1990-05-07 1996-06-18 Andrew J Feiring Method and apparatus for inducing the permeation of medication into internal tissue
US5056519A (en) 1990-05-14 1991-10-15 Vince Dennis J Unilateral diaphragmatic pacer
US5265604A (en) 1990-05-14 1993-11-30 Vince Dennis J Demand - diaphragmatic pacing (skeletal muscle pressure modified)
US5360443A (en) 1990-06-11 1994-11-01 Barone Hector D Aortic graft for repairing an abdominal aortic aneurysm
US5103804A (en) 1990-07-03 1992-04-14 Boston Scientific Corporation Expandable tip hemostatic probes and the like
US5135517A (en) 1990-07-19 1992-08-04 Catheter Research, Inc. Expandable tube-positioning apparatus
US5170803A (en) 1990-09-28 1992-12-15 Brunswick Biomedical Technologies, Inc. Esophageal displacement electrode
US5053033A (en) 1990-10-10 1991-10-01 Boston Advanced Technologies, Inc. Inhibition of restenosis by ultraviolet radiation
US5030645A (en) * 1990-10-15 1991-07-09 Merck & Co., Inc. Method of treating asthma using (S)-α-fluoromethyl-histidine and esters thereof
US5105826A (en) 1990-10-26 1992-04-21 Medtronic, Inc. Implantable defibrillation electrode and method of manufacture
US5174288A (en) 1990-11-30 1992-12-29 Medtronic, Inc. Method and apparatus for cardiac defibrillation
US5165420A (en) 1990-12-21 1992-11-24 Ballard Medical Products Bronchoalveolar lavage catheter
US5324255A (en) 1991-01-11 1994-06-28 Baxter International Inc. Angioplasty and ablative devices having onboard ultrasound components and devices and methods for utilizing ultrasound to treat or prevent vasopasm
US5345936A (en) 1991-02-15 1994-09-13 Cardiac Pathways Corporation Apparatus with basket assembly for endocardial mapping
US5409453A (en) 1992-08-12 1995-04-25 Vidamed, Inc. Steerable medical probe with stylets
US5415166A (en) 1991-02-15 1995-05-16 Cardiac Pathways Corporation Endocardial mapping apparatus and cylindrical semiconductor device mounting structure for use therewith and method
US5465717A (en) 1991-02-15 1995-11-14 Cardiac Pathways Corporation Apparatus and Method for ventricular mapping and ablation
RU2091054C1 (en) 1991-03-25 1997-09-27 Владивостокский государственный медицинский университет Method for treating asthmatic bronchitis in children affected with constitutional diathesis
US5116864A (en) 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
JPH06507097A (en) 1991-04-10 1994-08-11 ビーティージー・インターナショナル・インコーポレーテッド Defibrillator, temporary pacer catheter, and its implantation method
US5213576A (en) 1991-06-11 1993-05-25 Cordis Corporation Therapeutic porous balloon catheter
US5255678A (en) 1991-06-21 1993-10-26 Ecole Polytechnique Mapping electrode balloon
JPH0522345A (en) 1991-07-12 1993-01-29 Hitachi Ltd Optimum management decision system for maximum transfer unit
JPH05121329A (en) 1991-10-30 1993-05-18 Toshiba Corp Method and apparatus for manufacturing compound thin film
US5366443A (en) 1992-01-07 1994-11-22 Thapliyal And Eggers Partners Method and apparatus for advancing catheters through occluded body lumens
US6159194A (en) 1992-01-07 2000-12-12 Arthrocare Corporation System and method for electrosurgical tissue contraction
US6053172A (en) 1995-06-07 2000-04-25 Arthrocare Corporation Systems and methods for electrosurgical sinus surgery
US5231996A (en) 1992-01-28 1993-08-03 Medtronic, Inc. Removable endocardial lead
RU2053814C1 (en) 1992-02-11 1996-02-10 Новиков Валерий Николаевич Method for treatment of local endobronchitis
US5540681A (en) 1992-04-10 1996-07-30 Medtronic Cardiorhythm Method and system for radiofrequency ablation of tissue
US5269758A (en) 1992-04-29 1993-12-14 Taheri Syde A Intravascular catheter and method for treatment of hypothermia
US5443470A (en) 1992-05-01 1995-08-22 Vesta Medical, Inc. Method and apparatus for endometrial ablation
US5255679A (en) 1992-06-02 1993-10-26 Cardiac Pathways Corporation Endocardial catheter for mapping and/or ablation with an expandable basket structure having means for providing selective reinforcement and pressure sensing mechanism for use therewith, and method
US5324284A (en) 1992-06-05 1994-06-28 Cardiac Pathways, Inc. Endocardial mapping and ablation system utilizing a separately controlled ablation catheter and method
US5411025A (en) 1992-06-30 1995-05-02 Cordis Webster, Inc. Cardiovascular catheter with laterally stable basket-shaped electrode array
US5782239A (en) 1992-06-30 1998-07-21 Cordis Webster, Inc. Unique electrode configurations for cardiovascular electrode catheter with built-in deflection method and central puller wire
US5772590A (en) 1992-06-30 1998-06-30 Cordis Webster, Inc. Cardiovascular catheter with laterally stable basket-shaped electrode array with puller wire
WO1994003142A1 (en) 1992-07-30 1994-02-17 Temple University - Of The Commonwealth System Of Higher Education Direct manual cardiac compression device and method of use thereof
US5630794A (en) 1992-08-12 1997-05-20 Vidamed, Inc. Catheter tip and method of manufacturing
GB9219102D0 (en) 1992-09-09 1992-10-21 Fairfax Andrew J Flowmeters
US5313943A (en) 1992-09-25 1994-05-24 Ep Technologies, Inc. Catheters and methods for performing cardiac diagnosis and treatment
US5471982A (en) 1992-09-29 1995-12-05 Ep Technologies, Inc. Cardiac mapping and ablation systems
US6086581A (en) 1992-09-29 2000-07-11 Ep Technologies, Inc. Large surface cardiac ablation catheter that assumes a low profile during introduction into the heart
DE669839T1 (en) 1992-10-01 1996-10-10 Cardiac Pacemakers Inc STENT-LIKE STRUCTURE FOR DEFLICTION ELECTRODES.
US5431696A (en) 1992-10-13 1995-07-11 Atlee, Iii; John L. Esophageal probe for transeophageal cardiac stimulation
US5807306A (en) 1992-11-09 1998-09-15 Cortrak Medical, Inc. Polymer matrix drug delivery apparatus
US5348554A (en) 1992-12-01 1994-09-20 Cardiac Pathways Corporation Catheter for RF ablation with cooled electrode
US5545161A (en) 1992-12-01 1996-08-13 Cardiac Pathways Corporation Catheter for RF ablation having cooled electrode with electrically insulated sleeve
US5256141A (en) 1992-12-22 1993-10-26 Nelson Gencheff Biological material deployment method and apparatus
US5797960A (en) 1993-02-22 1998-08-25 Stevens; John H. Method and apparatus for thoracoscopic intracardiac procedures
US5315936A (en) * 1993-02-22 1994-05-31 Arrow Art Finishers, Inc. Erectable display stand
CA2158453C (en) * 1993-03-16 1999-11-16 Thomas F. Kordis Multiple electrode support structures
US5893847A (en) 1993-03-16 1999-04-13 Ep Technologies, Inc. Multiple electrode support structures with slotted hub and hoop spline elements
US5823189A (en) 1993-03-16 1998-10-20 Ep Technologies, Inc. Multiple electrode support structures with spline elements and over-molded hub
WO1994021170A1 (en) 1993-03-16 1994-09-29 Ep Technologies, Inc. Flexible circuit assemblies employing ribbon cable
US5417687A (en) 1993-04-30 1995-05-23 Medical Scientific, Inc. Bipolar electrosurgical trocar
US6749604B1 (en) 1993-05-10 2004-06-15 Arthrocare Corporation Electrosurgical instrument with axially-spaced electrodes
US5456667A (en) 1993-05-20 1995-10-10 Advanced Cardiovascular Systems, Inc. Temporary stenting catheter with one-piece expandable segment
US5571088A (en) 1993-07-01 1996-11-05 Boston Scientific Corporation Ablation catheters
DE69432148T2 (en) 1993-07-01 2003-10-16 Boston Scient Ltd CATHETER FOR IMAGE DISPLAY, DISPLAY OF ELECTRICAL SIGNALS AND ABLATION
GB9314640D0 (en) 1993-07-15 1993-08-25 Salim Aws S M Tunnellimg catheter
US5422362A (en) 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
US5507791A (en) * 1993-08-31 1996-04-16 Sit'ko; Sergei P. Microwave resonance therapy
US5490521A (en) 1993-08-31 1996-02-13 Medtronic, Inc. Ultrasound biopsy needle
US5908446A (en) 1994-07-07 1999-06-01 Cardiac Pathways Corporation Catheter assembly, catheter and multi-port introducer for use therewith
US5626618A (en) 1993-09-24 1997-05-06 The Ohio State University Mechanical adjunct to cardiopulmonary resuscitation (CPR), and an electrical adjunct to defibrillation countershock, cardiac pacing, and cardiac monitoring
US5415656A (en) 1993-09-28 1995-05-16 American Medical Systems, Inc. Electrosurgical apparatus
US5437665A (en) 1993-10-12 1995-08-01 Munro; Malcolm G. Electrosurgical loop electrode instrument for laparoscopic surgery
WO1995010322A1 (en) 1993-10-15 1995-04-20 Ep Technologies, Inc. Creating complex lesion patterns in body tissue
US5991650A (en) 1993-10-15 1999-11-23 Ep Technologies, Inc. Surface coatings for catheters, direct contacting diagnostic and therapeutic devices
US6071280A (en) 1993-11-08 2000-06-06 Rita Medical Systems, Inc. Multiple electrode ablation apparatus
US5536267A (en) 1993-11-08 1996-07-16 Zomed International Multiple electrode ablation apparatus
US6641580B1 (en) 1993-11-08 2003-11-04 Rita Medical Systems, Inc. Infusion array ablation apparatus
US5487385A (en) 1993-12-03 1996-01-30 Avitall; Boaz Atrial mapping and ablation catheter system
US5641326A (en) 1993-12-13 1997-06-24 Angeion Corporation Method and apparatus for independent atrial and ventricular defibrillation
US5423812A (en) 1994-01-31 1995-06-13 Ellman; Alan G. Electrosurgical stripping electrode for palatopharynx tissue
AUPM411494A0 (en) 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US6216043B1 (en) 1994-03-04 2001-04-10 Ep Technologies, Inc. Asymmetric multiple electrode support structures
CA2189004A1 (en) 1994-04-29 1995-11-09 Charles D. Lennox Resecting coagulated tissue
US5458596A (en) 1994-05-06 1995-10-17 Dorsal Orthopedic Corporation Method and apparatus for controlled contraction of soft tissue
US6152143A (en) 1994-05-09 2000-11-28 Somnus Medical Technologies, Inc. Method for treatment of air way obstructions
US5547469A (en) 1994-05-13 1996-08-20 Boston Scientific Corporation Apparatus for performing diagnostic and therapeutic modalities in the biliary tree
US5478309A (en) 1994-05-27 1995-12-26 William P. Sweezer, Jr. Catheter system and method for providing cardiopulmonary bypass pump support during heart surgery
US5836905A (en) * 1994-06-20 1998-11-17 Lemelson; Jerome H. Apparatus and methods for gene therapy
US5827277A (en) 1994-06-24 1998-10-27 Somnus Medical Technologies, Inc. Minimally invasive apparatus for internal ablation of turbinates
US6092528A (en) 1994-06-24 2000-07-25 Edwards; Stuart D. Method to treat esophageal sphincters
US5681308A (en) 1994-06-24 1997-10-28 Stuart D. Edwards Ablation apparatus for cardiac chambers
US5843077A (en) 1994-06-24 1998-12-01 Somnus Medical Technologies, Inc. Minimally invasive apparatus for internal ablation of turbinates with surface cooling
US6056744A (en) 1994-06-24 2000-05-02 Conway Stuart Medical, Inc. Sphincter treatment apparatus
US5505730A (en) 1994-06-24 1996-04-09 Stuart D. Edwards Thin layer ablation apparatus
US6006755A (en) 1994-06-24 1999-12-28 Edwards; Stuart D. Method to detect and treat aberrant myoelectric activity
ATE257675T1 (en) 1994-06-27 2004-01-15 Boston Scient Ltd NON-LINEAR CONTROL SYSTEMS FOR HEATING AND REMOVING BODY TISSUE
US5735846A (en) 1994-06-27 1998-04-07 Ep Technologies, Inc. Systems and methods for ablating body tissue using predicted maximum tissue temperature
US5680860A (en) 1994-07-07 1997-10-28 Cardiac Pathways Corporation Mapping and/or ablation catheter with coilable distal extremity and method for using same
DE4427106A1 (en) * 1994-07-30 1996-02-01 Otto Werner Woelky Process for control of tumours and skin cancer
US5623940A (en) 1994-08-02 1997-04-29 S.L.T. Japan Co., Ltd. Catheter apparatus with a sensor
US5454782A (en) 1994-08-11 1995-10-03 Perkins; Rodney C. Translumenal circumferential energy delivery device
US5522862A (en) 1994-09-21 1996-06-04 Medtronic, Inc. Method and apparatus for treating obstructive sleep apnea
US5549655A (en) 1994-09-21 1996-08-27 Medtronic, Inc. Method and apparatus for synchronized treatment of obstructive sleep apnea
US6142994A (en) 1994-10-07 2000-11-07 Ep Technologies, Inc. Surgical method and apparatus for positioning a diagnostic a therapeutic element within the body
US5885278A (en) 1994-10-07 1999-03-23 E.P. Technologies, Inc. Structures for deploying movable electrode elements
US5836947A (en) 1994-10-07 1998-11-17 Ep Technologies, Inc. Flexible structures having movable splines for supporting electrode elements
EP0784453B1 (en) 1994-10-07 2003-09-24 Boston Scientific Limited Flexible electrode support structure
US5740808A (en) 1996-10-28 1998-04-21 Ep Technologies, Inc Systems and methods for guilding diagnostic or therapeutic devices in interior tissue regions
US5899882A (en) * 1994-10-27 1999-05-04 Novoste Corporation Catheter apparatus for radiation treatment of a desired area in the vascular system of a patient
WO1996018349A2 (en) * 1994-12-13 1996-06-20 Torben Lorentzen An electrosurgical instrument for tissue ablation, an apparatus, and a method for providing a lesion in damaged and diseased tissue from a mammal
US5711305A (en) 1995-02-17 1998-01-27 Ep Technologies, Inc. Systems and methods for acquiring endocardially or epicardially paced electrocardiograms
US5630425A (en) 1995-02-17 1997-05-20 Ep Technologies, Inc. Systems and methods for adaptive filtering artifacts from composite signals
IT1277790B1 (en) 1995-02-17 1997-11-12 Tecres Spa METACARPO-FALANGEA AND INTERPHALANGE PROSTHESES FOR HAND OR FOOT JOINTS
ATE220307T1 (en) 1995-02-17 2002-07-15 Boston Scient Ltd ARRANGEMENT FOR SEQUENTIAL MEASURING BIOLOGICAL EVENTS
US5792064A (en) 1995-02-17 1998-08-11 Panescu; Dorin Systems and methods for analyzing cardiac biopotential morphologies by cross-correlation
CA2212808C (en) 1995-02-28 2007-12-04 Boston Scientific Corporation Polymeric implements for torque transmission
US6106524A (en) 1995-03-03 2000-08-22 Neothermia Corporation Methods and apparatus for therapeutic cauterization of predetermined volumes of biological tissue
US5588812A (en) 1995-04-19 1996-12-31 Nimbus, Inc. Implantable electric axial-flow blood pump
US5620438A (en) 1995-04-20 1997-04-15 Angiomedics Ii Incorporated Method and apparatus for treating vascular tissue following angioplasty to minimize restenosis
US5678535A (en) 1995-04-21 1997-10-21 Dimarco; Anthony Fortunato Method and apparatus for electrical stimulation of the respiratory muscles to achieve artificial ventilation in a patient
DK0782463T3 (en) 1995-04-28 2000-06-05 Target Therapeutics Inc High performance braided catheter
US5688267A (en) 1995-05-01 1997-11-18 Ep Technologies, Inc. Systems and methods for sensing multiple temperature conditions during tissue ablation
US5681280A (en) 1995-05-02 1997-10-28 Heart Rhythm Technologies, Inc. Catheter control system
US6575969B1 (en) 1995-05-04 2003-06-10 Sherwood Services Ag Cool-tip radiofrequency thermosurgery electrode system for tumor ablation
US5755753A (en) 1995-05-05 1998-05-26 Thermage, Inc. Method for controlled contraction of collagen tissue
US5817073A (en) * 1995-06-02 1998-10-06 Krespi; Yosef P. Apparatus for administering local anesthetics and therapeutic medications during endoscopic surgery
US6090104A (en) 1995-06-07 2000-07-18 Cordis Webster, Inc. Catheter with a spirally wound flat ribbon electrode
US5741248A (en) * 1995-06-07 1998-04-21 Temple University-Of The Commonwealth System Of Higher Education Fluorochemical liquid augmented cryosurgery
JPH0947518A (en) 1995-06-26 1997-02-18 Lederle Japan Ltd Optical fiber laser probe for photodynamic therapy
US6008211A (en) 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
WO1997004702A1 (en) 1995-07-28 1997-02-13 Ep Technologies, Inc. Systems and methods for conducting electrophysiological testing using high-voltage energy pulses to stun heart tissue
US5782827A (en) 1995-08-15 1998-07-21 Rita Medical Systems, Inc. Multiple antenna ablation apparatus and method with multiple sensor feedback
US5624439A (en) 1995-08-18 1997-04-29 Somnus Medical Technologies, Inc. Method and apparatus for treatment of air way obstructions
US5660175A (en) 1995-08-21 1997-08-26 Dayal; Bimal Endotracheal device
US6037149A (en) 1995-08-24 2000-03-14 Magainin Pharmaceuticals Inc. DNA encoding human asthma associated factor 1
US6496738B2 (en) 1995-09-06 2002-12-17 Kenneth L. Carr Dual frequency microwave heating apparatus
US6210367B1 (en) 1995-09-06 2001-04-03 Microwave Medical Systems, Inc. Intracorporeal microwave warming method and apparatus
US5848972A (en) 1995-09-15 1998-12-15 Children's Medical Center Corporation Method for endocardial activation mapping using a multi-electrode catheter
US6198970B1 (en) * 1995-10-27 2001-03-06 Esd Limited Liability Company Method and apparatus for treating oropharyngeal respiratory and oral motor neuromuscular disorders with electrical stimulation
US5574059A (en) 1995-10-27 1996-11-12 Cornell Research Foundation, Inc. Treating disorders mediated by vascular smooth muscle cell proliferation
US5837001A (en) 1995-12-08 1998-11-17 C. R. Bard Radio frequency energy delivery system for multipolar electrode catheters
US5891135A (en) * 1996-01-19 1999-04-06 Ep Technologies, Inc. Stem elements for securing tubing and electrical wires to expandable-collapsible electrode structures
US5846238A (en) 1996-01-19 1998-12-08 Ep Technologies, Inc. Expandable-collapsible electrode structures with distal end steering or manipulation
US5891136A (en) 1996-01-19 1999-04-06 Ep Technologies, Inc. Expandable-collapsible mesh electrode structures
US5904711A (en) 1996-02-08 1999-05-18 Heartport, Inc. Expandable thoracoscopic defibrillation catheter system and method
US5695471A (en) 1996-02-20 1997-12-09 Kriton Medical, Inc. Sealless rotary blood pump with passive magnetic radial bearings and blood immersed axial bearings
WO1997032532A1 (en) * 1996-03-05 1997-09-12 Vnus Medical Technologies, Inc. Vascular catheter-based system for heating tissue
US6139527A (en) 1996-03-05 2000-10-31 Vnus Medical Technologies, Inc. Method and apparatus for treating hemorrhoids
US6152899A (en) * 1996-03-05 2000-11-28 Vnus Medical Technologies, Inc. Expandable catheter having improved electrode design, and method for applying energy
US5755760A (en) 1996-03-11 1998-05-26 Medtronic, Inc. Deflectable catheter
NL1002598C2 (en) 1996-03-13 1997-09-17 Bootsman Holding Bv Method and device for processing substrate.
US6458121B1 (en) 1996-03-19 2002-10-01 Diapulse Corporation Of America Apparatus for athermapeutic medical treatments
US5699799A (en) 1996-03-26 1997-12-23 Siemens Corporate Research, Inc. Automatic determination of the curved axis of a 3-D tube-shaped object in image volume
US5694934A (en) 1996-04-17 1997-12-09 Beth Israel Hospital MR studies in which a paramagnetic gas is administered to a living patient
US5979456A (en) 1996-04-22 1999-11-09 Magovern; George J. Apparatus and method for reversibly reshaping a body part
US6036640A (en) 1996-04-29 2000-03-14 Medtronic, Inc. Device and method for repositioning the heart during surgery
US5810807A (en) 1996-05-22 1998-09-22 Ganz; Robert A. Sphincterotome with deflectable cutting plane and method of using the same
US5976709A (en) 1996-05-31 1999-11-02 Hitachi Kinzoku Kabushiki Kaisha Aluminum alloy member, with insert provided therein, possessing improved damping capacity and process for producing the same
US5782797A (en) 1996-06-06 1998-07-21 Scimed Life Systems, Inc. Therapeutic infusion device
US6743197B1 (en) 1996-07-10 2004-06-01 Novasys Medical, Inc. Treatment of discrete tissues in respiratory, urinary, circulatory, reproductive and digestive systems
US5919172A (en) 1996-07-17 1999-07-06 Becton, Dickinson And Company Hypodermic needle having a differential surface finish
US5755714A (en) * 1996-09-17 1998-05-26 Eclipse Surgical Technologies, Inc. Shaped catheter for transmyocardial revascularization
US5906636A (en) * 1996-09-20 1999-05-25 Texas Heart Institute Heat treatment of inflamed tissue
US6464697B1 (en) 1998-02-19 2002-10-15 Curon Medical, Inc. Stomach and adjoining tissue regions in the esophagus
KR100340252B1 (en) 1996-10-23 2002-06-12 사토 히로시 Method for manufacturing electrode for battery
US5848969A (en) 1996-10-28 1998-12-15 Ep Technologies, Inc. Systems and methods for visualizing interior tissue regions using expandable imaging structures
US5779669A (en) 1996-10-28 1998-07-14 C. R. Bard, Inc. Steerable catheter with fixed curve
US5752518A (en) 1996-10-28 1998-05-19 Ep Technologies, Inc. Systems and methods for visualizing interior regions of the body
US5908445A (en) 1996-10-28 1999-06-01 Ep Technologies, Inc. Systems for visualizing interior tissue regions including an actuator to move imaging element
US5904651A (en) 1996-10-28 1999-05-18 Ep Technologies, Inc. Systems and methods for visualizing tissue during diagnostic or therapeutic procedures
US5919147A (en) 1996-11-01 1999-07-06 Jain; Krishna M. Method and apparatus for measuring the vascular diameter of a vessel
US5833651A (en) 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
US6073052A (en) 1996-11-15 2000-06-06 Zelickson; Brian D. Device and method for treatment of gastroesophageal reflux disease
US6056769A (en) 1997-02-11 2000-05-02 Biointerventional Corporation Expansile device for use in blood vessels and tracts in the body and tension application device for use therewith and method
US5882329A (en) 1997-02-12 1999-03-16 Prolifix Medical, Inc. Apparatus and method for removing stenotic material from stents
US5999855A (en) 1997-02-28 1999-12-07 Dimarco; Anthony F. Method and apparatus for electrical activation of the expiratory muscles to restore cough
US5897554A (en) 1997-03-01 1999-04-27 Irvine Biomedical, Inc. Steerable catheter having a loop electrode
US6063078A (en) 1997-03-12 2000-05-16 Medtronic, Inc. Method and apparatus for tissue ablation
US5954661A (en) 1997-03-31 1999-09-21 Thomas Jefferson University Tissue characterization and treatment using pacing
US6634363B1 (en) 1997-04-07 2003-10-21 Broncus Technologies, Inc. Methods of treating lungs having reversible obstructive pulmonary disease
US7027869B2 (en) 1998-01-07 2006-04-11 Asthmatx, Inc. Method for treating an asthma attack
US6200333B1 (en) 1997-04-07 2001-03-13 Broncus Technologies, Inc. Bronchial stenter
US6083255A (en) 1997-04-07 2000-07-04 Broncus Technologies, Inc. Bronchial stenter
US7425212B1 (en) 1998-06-10 2008-09-16 Asthmatx, Inc. Devices for modification of airways by transfer of energy
US6273907B1 (en) * 1997-04-07 2001-08-14 Broncus Technologies, Inc. Bronchial stenter
US6283988B1 (en) 1997-04-07 2001-09-04 Broncus Technologies, Inc. Bronchial stenter having expandable electrodes
US5972026A (en) 1997-04-07 1999-10-26 Broncus Technologies, Inc. Bronchial stenter having diametrically adjustable electrodes
US6411852B1 (en) 1997-04-07 2002-06-25 Broncus Technologies, Inc. Modification of airways by application of energy
US6488673B1 (en) * 1997-04-07 2002-12-03 Broncus Technologies, Inc. Method of increasing gas exchange of a lung
US5971983A (en) 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6217576B1 (en) 1997-05-19 2001-04-17 Irvine Biomedical Inc. Catheter probe for treating focal atrial fibrillation in pulmonary veins
US6050992A (en) 1997-05-19 2000-04-18 Radiotherapeutics Corporation Apparatus and method for treating tissue with multiple electrodes
US7255693B1 (en) 1997-05-23 2007-08-14 Csa Medical, Inc. Heated catheter used in cryotherapy
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
US6582423B1 (en) 1997-06-13 2003-06-24 Arthrocare Corporation Electrosurgical systems and methods for recanalization of occluded body lumens
US6251109B1 (en) 1997-06-27 2001-06-26 Daig Corporation Process and device for the treatment of atrial arrhythmia
US6500174B1 (en) 1997-07-08 2002-12-31 Atrionix, Inc. Circumferential ablation device assembly and methods of use and manufacture providing an ablative circumferential band along an expandable member
US6547788B1 (en) 1997-07-08 2003-04-15 Atrionx, Inc. Medical device with sensor cooperating with expandable member
US6139571A (en) 1997-07-09 2000-10-31 Fuller Research Corporation Heated fluid surgical instrument
US6626903B2 (en) 1997-07-24 2003-09-30 Rex Medical, L.P. Surgical biopsy device
US5891138A (en) 1997-08-11 1999-04-06 Irvine Biomedical, Inc. Catheter system having parallel electrodes
US5916235A (en) 1997-08-13 1999-06-29 The Regents Of The University Of California Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities
US5964782A (en) * 1997-09-18 1999-10-12 Scimed Life Systems, Inc. Closure device and method
US5954717A (en) 1997-09-25 1999-09-21 Radiotherapeutics Corporation Method and system for heating solid tissue
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6045549A (en) 1997-09-30 2000-04-04 Somnus Medical Technologies, Inc. Tissue ablation apparatus and device for use therein and method
EP0908713A1 (en) 1997-10-06 1999-04-14 Claud S. Gordon Company Temperature instrumented semiconductor wafer
US6071281A (en) 1998-05-05 2000-06-06 Ep Technologies, Inc. Surgical method and apparatus for positioning a diagnostic or therapeutic element within the body and remote power control unit for use with same
US5893835A (en) 1997-10-10 1999-04-13 Ethicon Endo-Surgery, Inc. Ultrasonic clamp coagulator apparatus having dual rotational positioning
US6645200B1 (en) 1997-10-10 2003-11-11 Scimed Life Systems, Inc. Method and apparatus for positioning a diagnostic or therapeutic element within the body and tip electrode for use with same
US6917834B2 (en) 1997-12-03 2005-07-12 Boston Scientific Scimed, Inc. Devices and methods for creating lesions in endocardial and surrounding tissue to isolate focal arrhythmia substrates
US7921855B2 (en) 1998-01-07 2011-04-12 Asthmatx, Inc. Method for treating an asthma attack
US6080149A (en) * 1998-01-09 2000-06-27 Radiotherapeutics, Corporation Method and apparatus for monitoring solid tissue heating
US6200311B1 (en) 1998-01-20 2001-03-13 Eclipse Surgical Technologies, Inc. Minimally invasive TMR device
US6355031B1 (en) 1998-02-19 2002-03-12 Curon Medical, Inc. Control systems for multiple electrode arrays to create lesions in tissue regions at or near a sphincter
US6258087B1 (en) 1998-02-19 2001-07-10 Curon Medical, Inc. Expandable electrode assemblies for forming lesions to treat dysfunction in sphincters and adjoining tissue regions
US6331166B1 (en) * 1998-03-03 2001-12-18 Senorx, Inc. Breast biopsy system and method
US6142993A (en) 1998-02-27 2000-11-07 Ep Technologies, Inc. Collapsible spline structure using a balloon as an expanding actuator
AU3072499A (en) * 1998-03-09 1999-09-27 Cardiofocus, Inc. Thermal treatment device including expansion element
JP2002506672A (en) 1998-03-19 2002-03-05 オーレイテック インターヴェンションズ インコーポレイテッド Catheter for delivering energy to the surgical site
US6053909A (en) * 1998-03-27 2000-04-25 Shadduck; John H. Ionothermal delivery system and technique for medical procedures
US6003517A (en) 1998-04-30 1999-12-21 Ethicon Endo-Surgery, Inc. Method for using an electrosurgical device on lung tissue
US6161047A (en) 1998-04-30 2000-12-12 Medtronic Inc. Apparatus and method for expanding a stimulation lead body in situ
US6045550A (en) 1998-05-05 2000-04-04 Cardiac Peacemakers, Inc. Electrode having non-joined thermocouple for providing multiple temperature-sensitive junctions
US6558378B2 (en) 1998-05-05 2003-05-06 Cardiac Pacemakers, Inc. RF ablation system and method having automatic temperature control
US5880346A (en) * 1998-05-06 1999-03-09 Monsanto Corporation Soybean cultivar 94502395194
US6327505B1 (en) * 1998-05-07 2001-12-04 Medtronic, Inc. Method and apparatus for rf intraluminal reduction and occlusion
US6493589B1 (en) 1998-05-07 2002-12-10 Medtronic, Inc. Methods and apparatus for treatment of pulmonary conditions
US6001054A (en) 1998-05-19 1999-12-14 Regulla; D. F. Method and apparatus for differential energy application for local dose enhancement of ionizing radiation
US6241727B1 (en) 1998-05-27 2001-06-05 Irvine Biomedical, Inc. Ablation catheter system having circular lesion capabilities
US5997534A (en) 1998-06-08 1999-12-07 Tu; Hosheng Medical ablation device and methods thereof
US8181656B2 (en) 1998-06-10 2012-05-22 Asthmatx, Inc. Methods for treating airways
US20070123958A1 (en) 1998-06-10 2007-05-31 Asthmatx, Inc. Apparatus for treating airways in the lung
US7198635B2 (en) 2000-10-17 2007-04-03 Asthmatx, Inc. Modification of airways by application of energy
US20070106348A1 (en) 1998-06-10 2007-05-10 Asthmatx, Inc. Method for treating airways in the lung
US6322559B1 (en) 1998-07-06 2001-11-27 Vnus Medical Technologies, Inc. Electrode catheter having coil structure
US6296639B1 (en) 1999-02-12 2001-10-02 Novacept Apparatuses and methods for interstitial tissue removal
US6212433B1 (en) 1998-07-28 2001-04-03 Radiotherapeutics Corporation Method for treating tumors near the surface of an organ
US6322584B2 (en) 1998-07-31 2001-11-27 Surx, Inc. Temperature sensing devices and methods to shrink tissues
US5992419A (en) 1998-08-20 1999-11-30 Mmtc, Inc. Method employing a tissue-heating balloon catheter to produce a "biological stent" in an orifice or vessel of a patient's body
US5980563A (en) 1998-08-31 1999-11-09 Tu; Lily Chen Ablation apparatus and methods for treating atherosclerosis
US6245065B1 (en) 1998-09-10 2001-06-12 Scimed Life Systems, Inc. Systems and methods for controlling power in an electrosurgical probe
US6123702A (en) 1998-09-10 2000-09-26 Scimed Life Systems, Inc. Systems and methods for controlling power in an electrosurgical probe
US6123703A (en) 1998-09-19 2000-09-26 Tu; Lily Chen Ablation catheter and methods for treating tissues
US6269813B1 (en) 1999-01-15 2001-08-07 Respironics, Inc. Tracheal gas insufflation bypass and phasic delivery system and method
US6582427B1 (en) 1999-03-05 2003-06-24 Gyrus Medical Limited Electrosurgery system
US6409723B1 (en) 1999-04-02 2002-06-25 Stuart D. Edwards Treating body tissue by applying energy and substances
US6325797B1 (en) 1999-04-05 2001-12-04 Medtronic, Inc. Ablation catheter and method for isolating a pulmonary vein
US6149647A (en) 1999-04-19 2000-11-21 Tu; Lily Chen Apparatus and methods for tissue treatment
US6939346B2 (en) 1999-04-21 2005-09-06 Oratec Interventions, Inc. Method and apparatus for controlling a temperature-controlled probe
US6270476B1 (en) 1999-04-23 2001-08-07 Cryocath Technologies, Inc. Catheter
US6235024B1 (en) 1999-06-21 2001-05-22 Hosheng Tu Catheters system having dual ablation capability
US6364878B1 (en) 1999-07-07 2002-04-02 Cardiac Pacemakers, Inc. Percutaneous transluminal ablation catheter manipulation tool
US6200332B1 (en) 1999-07-09 2001-03-13 Ceramoptec Industries, Inc. Device and method for underskin laser treatments
US6749606B2 (en) 1999-08-05 2004-06-15 Thomas Keast Devices for creating collateral channels
US6264653B1 (en) 1999-09-24 2001-07-24 C. R. Band, Inc. System and method for gauging the amount of electrode-tissue contact using pulsed radio frequency energy
US20030069570A1 (en) 1999-10-02 2003-04-10 Witzel Thomas H. Methods for repairing mitral valve annulus percutaneously
US20040249401A1 (en) 1999-10-05 2004-12-09 Omnisonics Medical Technologies, Inc. Apparatus and method for an ultrasonic medical device with a non-compliant balloon
US6287304B1 (en) 1999-10-15 2001-09-11 Neothermia Corporation Interstitial cauterization of tissue volumes with electrosurgically deployed electrodes
US6529756B1 (en) 1999-11-22 2003-03-04 Scimed Life Systems, Inc. Apparatus for mapping and coagulating soft tissue in or around body orifices
US6589235B2 (en) 2000-01-21 2003-07-08 The Regents Of The University Of California Method and apparatus for cartilage reshaping by radiofrequency heating
US6723091B2 (en) 2000-02-22 2004-04-20 Gyrus Medical Limited Tissue resurfacing
US6544226B1 (en) 2000-03-13 2003-04-08 Curon Medical, Inc. Operative devices that can be removably fitted on catheter bodies to treat tissue regions in the body
US6770070B1 (en) 2000-03-17 2004-08-03 Rita Medical Systems, Inc. Lung treatment apparatus and method
US20010031981A1 (en) 2000-03-31 2001-10-18 Evans Michael A. Method and device for locating guidewire and treating chronic total occlusions
US6640120B1 (en) 2000-10-05 2003-10-28 Scimed Life Systems, Inc. Probe assembly for mapping and ablating pulmonary vein tissue and method of using same
EP1326549B1 (en) 2000-10-17 2005-12-21 Asthmatx, Inc. Modification of airways by application of energy
US7104987B2 (en) 2000-10-17 2006-09-12 Asthmatx, Inc. Control system and process for application of energy to airway walls and other mediums
US6575623B2 (en) 2000-11-10 2003-06-10 Cardiostream, Inc. Guide wire having extendable contact sensors for measuring temperature of vessel walls
US7785323B2 (en) 2000-12-04 2010-08-31 Boston Scientific Scimed, Inc. Loop structure including inflatable therapeutic device
US6676657B2 (en) 2000-12-07 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services Endoluminal radiofrequency cauterization system
US20020087151A1 (en) 2000-12-29 2002-07-04 Afx, Inc. Tissue ablation apparatus with a sliding ablation instrument and method
US6699243B2 (en) 2001-09-19 2004-03-02 Curon Medical, Inc. Devices, systems and methods for treating tissue regions of the body
US6620159B2 (en) 2001-06-06 2003-09-16 Scimed Life Systems, Inc. Conductive expandable electrode body and method of manufacturing the same
US6802843B2 (en) 2001-09-13 2004-10-12 Csaba Truckai Electrosurgical working end with resistive gradient electrodes
JP3607231B2 (en) 2001-09-28 2005-01-05 有限会社日本エレクテル High frequency heating balloon catheter
US6635056B2 (en) 2001-10-09 2003-10-21 Cardiac Pacemakers, Inc. RF ablation apparatus and method using amplitude control
US6895267B2 (en) 2001-10-24 2005-05-17 Scimed Life Systems, Inc. Systems and methods for guiding and locating functional elements on medical devices positioned in a body
US6669693B2 (en) 2001-11-13 2003-12-30 Mayo Foundation For Medical Education And Research Tissue ablation device and methods of using
US6893436B2 (en) 2002-01-03 2005-05-17 Afx, Inc. Ablation instrument having a flexible distal portion
US20030187430A1 (en) 2002-03-15 2003-10-02 Vorisek James C. System and method for measuring power at tissue during RF ablation
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
DE10218894A1 (en) 2002-04-26 2003-11-13 Storz Endoskop Prod Gmbh Device for monitoring medical devices
US6881213B2 (en) 2002-06-28 2005-04-19 Ethicon, Inc. Device and method to expand treatment array
US6866662B2 (en) 2002-07-23 2005-03-15 Biosense Webster, Inc. Ablation catheter having stabilizing array
US20040082947A1 (en) 2002-10-25 2004-04-29 The Regents Of The University Of Michigan Ablation catheters
US20040153056A1 (en) 2002-11-11 2004-08-05 Berchtold Holding Gmbh, A German Corporation Probe
US7131445B2 (en) 2002-12-23 2006-11-07 Gyrus Medical Limited Electrosurgical method and apparatus
US7186251B2 (en) 2003-03-27 2007-03-06 Cierra, Inc. Energy based devices and methods for treatment of patent foramen ovale
US20050171396A1 (en) 2003-10-20 2005-08-04 Cyberheart, Inc. Method for non-invasive lung treatment
WO2005039689A2 (en) 2003-10-24 2005-05-06 Sinus Rhythm Technologies, Inc. Methods and devices for creating cardiac electrical blocks
US20050096644A1 (en) 2003-10-30 2005-05-05 Hall Jeffrey A. Energy delivery optimization for RF duty cycle for lesion creation
US7377918B2 (en) 2004-04-28 2008-05-27 Gyrus Medical Limited Electrosurgical method and apparatus
US7906124B2 (en) 2004-09-18 2011-03-15 Asthmatx, Inc. Inactivation of smooth muscle tissue
US7553309B2 (en) 2004-10-08 2009-06-30 Covidien Ag Electrosurgical system employing multiple electrodes and method thereof
US20060089637A1 (en) 2004-10-14 2006-04-27 Werneth Randell L Ablation catheter
WO2006052940A2 (en) 2004-11-05 2006-05-18 Asthmatx, Inc. Medical device with procedure improvement features
US7200445B1 (en) 2005-10-21 2007-04-03 Asthmatx, Inc. Energy delivery devices and methods
US7949407B2 (en) 2004-11-05 2011-05-24 Asthmatx, Inc. Energy delivery devices and methods
US20070093802A1 (en) 2005-10-21 2007-04-26 Danek Christopher J Energy delivery devices and methods
US20060135953A1 (en) 2004-12-22 2006-06-22 Wlodzimierz Kania Tissue ablation system including guidewire with sensing element
EP1874211B1 (en) 2005-04-21 2017-05-31 Boston Scientific Scimed, Inc. Control devices for energy delivery
EP2759276A1 (en) 2005-06-20 2014-07-30 Medtronic Ablation Frontiers LLC Ablation catheter
EP2037840B2 (en) 2006-06-28 2019-02-20 Medtronic Ardian Luxembourg S.à.r.l. Systems for thermally-induced renal neuromodulation
US7931647B2 (en) 2006-10-20 2011-04-26 Asthmatx, Inc. Method of delivering energy to a lung airway using markers
TW200942282A (en) 2007-12-05 2009-10-16 Reset Medical Inc Method for cryospray ablation
AU2009244058B2 (en) 2008-05-09 2015-07-02 Nuvaira, Inc Systems, assemblies, and methods for treating a bronchial tree
US20100160906A1 (en) 2008-12-23 2010-06-24 Asthmatx, Inc. Expandable energy delivery devices having flexible conductive elements and associated systems and methods

Patent Citations (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1216183A (en) * 1916-09-18 1917-02-13 Charles M Swingle Electrotherapeutic rejuvenator.
US2072346A (en) * 1934-10-04 1937-03-02 Ward R Smith Drainage tube
US3568659A (en) * 1968-09-24 1971-03-09 James N Karnegis Disposable percutaneous intracardiac pump and method of pumping blood
US4565200A (en) * 1980-09-24 1986-01-21 Cosman Eric R Universal lesion and recording electrode system
US4502490A (en) * 1980-10-28 1985-03-05 Antec Systems Limited Patient monitoring equipment, probe for use therewith, and method of measuring anesthesia based on oesophagal contractions
US4503855A (en) * 1981-12-31 1985-03-12 Harald Maslanka High frequency surgical snare electrode
US4567882A (en) * 1982-12-06 1986-02-04 Vanderbilt University Method for locating the illuminated tip of an endotracheal tube
US4646737A (en) * 1983-06-13 1987-03-03 Laserscope, Inc. Localized heat applying medical device
US4799479A (en) * 1984-10-24 1989-01-24 The Beth Israel Hospital Association Method and apparatus for angioplasty
US4643186A (en) * 1985-10-30 1987-02-17 Rca Corporation Percutaneous transluminal microwave catheter angioplasty
US5500011A (en) * 1986-11-14 1996-03-19 Desai; Jawahar M. Catheter for mapping and ablation and method therefor
US4802492A (en) * 1987-03-11 1989-02-07 National Jewish Center For Immunology And Respiratory Medicine Method for determining respiratory function
US4895557A (en) * 1987-12-07 1990-01-23 Nimbus Medical, Inc. Drive mechanism for powering intravascular blood pumps
US4907589A (en) * 1988-04-29 1990-03-13 Cosman Eric R Automatic over-temperature control apparatus for a therapeutic heating device
US4906229A (en) * 1988-05-03 1990-03-06 Nimbus Medical, Inc. High-frequency transvalvular axisymmetric blood pump
US4908012A (en) * 1988-08-08 1990-03-13 Nimbus Medical, Inc. Chronic ventricular assist system
US5191883A (en) * 1988-10-28 1993-03-09 Prutech Research And Development Partnership Ii Device for heating tissue in a patient's body
US5496311A (en) * 1988-10-28 1996-03-05 Boston Scientific Corporation Physiologic low stress angioplasty
US4985014A (en) * 1989-07-11 1991-01-15 Orejola Wilmo C Ventricular venting loop
US5084044A (en) * 1989-07-14 1992-01-28 Ciron Corporation Apparatus for endometrial ablation and method of using same
US5292331A (en) * 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5707352A (en) * 1989-08-28 1998-01-13 Alliance Pharmaceutical Corp. Pulmonary delivery of therapeutic agent
US5100388A (en) * 1989-09-15 1992-03-31 Interventional Thermodynamics, Inc. Method and device for thermal ablation of hollow body organs
US4991603A (en) * 1989-10-30 1991-02-12 Siemens-Pacesetter, Inc. Transvenously placed defibrillation leads via an inferior vena cava access site and method of use
US5096916A (en) * 1990-05-07 1992-03-17 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
US5078716A (en) * 1990-05-11 1992-01-07 Doll Larry F Electrosurgical apparatus for resecting abnormal protruding growth
US5400778A (en) * 1990-06-18 1995-03-28 Siemens-Elema Ab Method and device for reduction of rebreathing of gas from dead space
US5188602A (en) * 1990-07-12 1993-02-23 Interventional Thermodynamics, Inc. Method and device for delivering heat to hollow body organs
US5100423A (en) * 1990-08-21 1992-03-31 Medical Engineering & Development Institute, Inc. Ablation catheter
US5496271A (en) * 1990-09-14 1996-03-05 American Medical Systems, Inc. Combined hyperthermia and dilation catheter
US5383917A (en) * 1991-07-05 1995-01-24 Jawahar M. Desai Device and method for multi-phase radio-frequency ablation
US5730704A (en) * 1992-02-24 1998-03-24 Avitall; Boaz Loop electrode array mapping and ablation catheter for cardiac chambers
US5281218A (en) * 1992-06-05 1994-01-25 Cardiac Pathways Corporation Catheter having needle electrode for radiofrequency ablation
US6852091B2 (en) * 1992-08-12 2005-02-08 Medtronic Vidamed, Inc. Medical probe device and method
US5293869A (en) * 1992-09-25 1994-03-15 Ep Technologies, Inc. Cardiac probe with dynamic support for maintaining constant surface contact during heart systole and diastole
US5871443A (en) * 1992-09-25 1999-02-16 Ep Technologies, Inc. Cardiac mapping and ablation systems
US5393207A (en) * 1993-01-21 1995-02-28 Nimbus, Inc. Blood pump with disposable rotor assembly
US5725525A (en) * 1993-03-16 1998-03-10 Ep Technologies, Inc. Multiple electrode support structures with integral hub and spline elements
US5860974A (en) * 1993-07-01 1999-01-19 Boston Scientific Corporation Heart ablation catheter with expandable electrode and method of coupling energy to an electrode on a catheter shaft
US5396887A (en) * 1993-09-23 1995-03-14 Cardiac Pathways Corporation Apparatus and method for detecting contact pressure
US5607462A (en) * 1993-09-24 1997-03-04 Cardiac Pathways Corporation Catheter assembly, catheter and multi-catheter introducer for use therewith
US5496312A (en) * 1993-10-07 1996-03-05 Valleylab Inc. Impedance and temperature generator control
US5730128A (en) * 1993-10-12 1998-03-24 Cardiac Pathways Corporation Endocardial mapping apparatus
US5400783A (en) * 1993-10-12 1995-03-28 Cardiac Pathways Corporation Endocardial mapping apparatus with rotatable arm and method
US6514246B1 (en) * 1993-10-14 2003-02-04 Ep Technologies, Inc. Systems and methods for forming large lesions in body tissue using curvilinear electrode elements
US5881727A (en) * 1993-10-14 1999-03-16 Ep Technologies, Inc. Integrated cardiac mapping and ablation probe
US5871523A (en) * 1993-10-15 1999-02-16 Ep Technologies, Inc. Helically wound radio-frequency emitting electrodes for creating lesions in body tissue
US5599345A (en) * 1993-11-08 1997-02-04 Zomed International, Inc. RF treatment apparatus
US5394880A (en) * 1994-03-17 1995-03-07 Atlee, Iii; John L. Esophageal stethoscope
US5598848A (en) * 1994-03-31 1997-02-04 Ep Technologies, Inc. Systems and methods for positioning multiple electrode structures in electrical contact with the myocardium
US6009877A (en) * 1994-06-24 2000-01-04 Edwards; Stuart D. Method for treating a sphincter
US5722401A (en) * 1994-10-19 1998-03-03 Cardiac Pathways Corporation Endocardial mapping and/or ablation catheter probe
US5707336A (en) * 1995-01-09 1998-01-13 Cardassist Incorporated Ventricular assist device
US5722416A (en) * 1995-02-17 1998-03-03 Ep Technologies, Inc. Systems and methods for analyzing biopotential morphologies in heart tissue to locate potential ablation sites
US5605157A (en) * 1995-02-17 1997-02-25 Ep Technologies, Inc. Systems and methods for filtering signals derived from biological events
US5595183A (en) * 1995-02-17 1997-01-21 Ep Technologies, Inc. Systems and methods for examining heart tissue employing multiple electrode structures and roving electrodes
US5601088A (en) * 1995-02-17 1997-02-11 Ep Technologies, Inc. Systems and methods for filtering artifacts from composite signals
US5868740A (en) * 1995-03-24 1999-02-09 Board Of Regents-Univ Of Nebraska Method for volumetric tissue ablation
US5707218A (en) * 1995-04-19 1998-01-13 Nimbus, Inc. Implantable electric axial-flow blood pump with blood cooled bearing
US5607419A (en) * 1995-04-24 1997-03-04 Angiomedics Ii Inc. Method and apparatus for treating vessel wall with UV radiation following angioplasty
US6837888B2 (en) * 1995-06-07 2005-01-04 Arthrocare Corporation Electrosurgical probe with movable return electrode and methods related thereto
US5865791A (en) * 1995-06-07 1999-02-02 E.P. Technologies Inc. Atrial appendage stasis reduction procedure and devices
US6179833B1 (en) * 1995-06-09 2001-01-30 Engineering & Research Associates, Inc. Apparatus for thermal ablation
US6039731A (en) * 1995-06-09 2000-03-21 Engineering & Research Associates, Inc. Apparatus and method for determining the extent of ablation
US5873852A (en) * 1995-07-10 1999-02-23 Interventional Technologies Device for injecting fluid into a wall of a blood vessel
US6023638A (en) * 1995-07-28 2000-02-08 Scimed Life Systems, Inc. System and method for conducting electrophysiological testing using high-voltage energy pulses to stun tissue
US5727569A (en) * 1996-02-20 1998-03-17 Cardiothoracic Systems, Inc. Surgical devices for imposing a negative pressure to fix the position of cardiac tissue during surgery
US5728094A (en) * 1996-02-23 1998-03-17 Somnus Medical Technologies, Inc. Method and apparatus for treatment of air way obstructions
US5730726A (en) * 1996-03-04 1998-03-24 Klingenstein; Ralph James Apparatus and method for removing fecal impaction
US6036687A (en) * 1996-03-05 2000-03-14 Vnus Medical Technologies, Inc. Method and apparatus for treating venous insufficiency
US6033397A (en) * 1996-03-05 2000-03-07 Vnus Medical Technologies, Inc. Method and apparatus for treating esophageal varices
US5863291A (en) * 1996-04-08 1999-01-26 Cardima, Inc. Linear ablation assembly
US6346104B2 (en) * 1996-04-30 2002-02-12 Western Sydney Area Health Service System for simultaneous unipolar multi-electrode ablation
US5882346A (en) * 1996-07-15 1999-03-16 Cardiac Pathways Corporation Shapable catheter using exchangeable core and method of use
US5855577A (en) * 1996-09-17 1999-01-05 Eclipse Surgical Technologies, Inc. Bow shaped catheter
US6016437A (en) * 1996-10-21 2000-01-18 Irvine Biomedical, Inc. Catheter probe system with inflatable soft shafts
US5722403A (en) * 1996-10-28 1998-03-03 Ep Technologies, Inc. Systems and methods using a porous electrode for ablating and visualizing interior tissue regions
US5873865A (en) * 1997-02-07 1999-02-23 Eclipse Surgical Technologies, Inc. Spiral catheter with multiple guide holes
US5730741A (en) * 1997-02-07 1998-03-24 Eclipse Surgical Technologies, Inc. Guided spiral catheter
US5876340A (en) * 1997-04-17 1999-03-02 Irvine Biomedical, Inc. Ablation apparatus with ultrasonic imaging capabilities
US5876399A (en) * 1997-05-28 1999-03-02 Irvine Biomedical, Inc. Catheter system and methods thereof
US6024740A (en) * 1997-07-08 2000-02-15 The Regents Of The University Of California Circumferential ablation device assembly
US6014579A (en) * 1997-07-21 2000-01-11 Cardiac Pathways Corp. Endocardial mapping catheter with movable electrode
US6010500A (en) * 1997-07-21 2000-01-04 Cardiac Pathways Corporation Telescoping apparatus and method for linear lesion ablation
US7992572B2 (en) * 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
US6849073B2 (en) * 1998-07-07 2005-02-01 Medtronic, Inc. Apparatus and method for creating, maintaining, and controlling a virtual electrode used for the ablation of tissue
US6029091A (en) * 1998-07-09 2000-02-22 Irvine Biomedical, Inc. Catheter system having lattice electrodes
US6338727B1 (en) * 1998-08-13 2002-01-15 Alsius Corporation Indwelling heat exchange catheter and method of using same
US6183468B1 (en) * 1998-09-10 2001-02-06 Scimed Life Systems, Inc. Systems and methods for controlling power in an electrosurgical probe
US6036689A (en) * 1998-09-24 2000-03-14 Tu; Lily Chen Ablation device for treating atherosclerotic tissues
US6526320B2 (en) * 1998-11-16 2003-02-25 United States Surgical Corporation Apparatus for thermal treatment of tissue
US6338836B1 (en) * 1999-09-28 2002-01-15 Siemens Aktiengesellschaft Asthma analysis method employing hyperpolarized gas and magnetic resonance imaging
US6840243B2 (en) * 2000-03-04 2005-01-11 Emphasys Medical, Inc. Methods and devices for use in performing pulmonary procedures
US8251070B2 (en) * 2000-03-27 2012-08-28 Asthmatx, Inc. Methods for treating airways
US6673068B1 (en) * 2000-04-12 2004-01-06 Afx, Inc. Electrode arrangement for use in a medical instrument
US6692492B2 (en) * 2001-11-28 2004-02-17 Cardiac Pacemaker, Inc. Dielectric-coated ablation electrode having a non-coated window with thermal sensors
US6852110B2 (en) * 2002-08-01 2005-02-08 Solarant Medical, Inc. Needle deployment for temperature sensing from an electrode
US20080004596A1 (en) * 2006-05-25 2008-01-03 Palo Alto Institute Delivery of agents by microneedle catheter
US20090018538A1 (en) * 2007-07-12 2009-01-15 Asthmatx, Inc. Systems and methods for delivering energy to passageways in a patient
US20090030477A1 (en) * 2007-07-24 2009-01-29 Asthmatx, Inc. System and method for controlling power based on impedance detection, such as controlling power to tissue treatment devices
US20090043301A1 (en) * 2007-08-09 2009-02-12 Asthmatx, Inc. Monopolar energy delivery devices and methods for controlling current density in tissue

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033317B2 (en) 1997-04-07 2021-06-15 Boston Scientific Scimed, Inc. Methods for treating a lung
US10058370B2 (en) 1997-04-07 2018-08-28 Boston Scientific Scimed, Inc. Method for treating a lung
US9956023B2 (en) 1997-04-07 2018-05-01 Boston Scientific Scimed, Inc. System for treating a lung
US8640711B2 (en) 1997-04-07 2014-02-04 Asthmatx, Inc. Method for treating an asthma attack
US7938123B2 (en) 1997-04-07 2011-05-10 Asthmatx, Inc. Modification of airways by application of cryo energy
US9027564B2 (en) 1997-04-07 2015-05-12 Asthmatx, Inc. Method for treating a lung
US8944071B2 (en) 1997-04-07 2015-02-03 Asthmatx, Inc. Method for treating an asthma attack
US8161978B2 (en) 1997-04-07 2012-04-24 Asthmatx, Inc. Methods for treating asthma by damaging nerve tissue
US8267094B2 (en) 1997-04-07 2012-09-18 Asthmatx, Inc. Modification of airways by application of ultrasound energy
US7921855B2 (en) 1998-01-07 2011-04-12 Asthmatx, Inc. Method for treating an asthma attack
US8584681B2 (en) 1998-01-07 2013-11-19 Asthmatx, Inc. Method for treating an asthma attack
US9789331B2 (en) 1998-01-07 2017-10-17 Boston Scientific Scimed, Inc. Methods of treating a lung
US7992572B2 (en) 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
US8443810B2 (en) 1998-06-10 2013-05-21 Asthmatx, Inc. Methods of reducing mucus in airways
US8464723B2 (en) 1998-06-10 2013-06-18 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
US8181656B2 (en) 1998-06-10 2012-05-22 Asthmatx, Inc. Methods for treating airways
US9358024B2 (en) 2000-03-27 2016-06-07 Asthmatx, Inc. Methods for treating airways
US8459268B2 (en) 2000-03-27 2013-06-11 Asthmatx, Inc. Methods for treating airways
US8251070B2 (en) 2000-03-27 2012-08-28 Asthmatx, Inc. Methods for treating airways
US10561458B2 (en) 2000-03-27 2020-02-18 Boston Scientific Scimed, Inc. Methods for treating airways
US10278766B2 (en) 2000-03-27 2019-05-07 Boston Scientific Scimed, Inc. Methods for treating airways
US8465486B2 (en) 2000-10-17 2013-06-18 Asthmatx, Inc. Modification of airways by application of energy
US8257413B2 (en) 2000-10-17 2012-09-04 Asthmatx, Inc. Modification of airways by application of energy
US9931163B2 (en) 2000-10-17 2018-04-03 Boston Scientific Scimed, Inc. Energy delivery devices
US8888769B2 (en) 2000-10-17 2014-11-18 Asthmatx, Inc. Control system and process for application of energy to airway walls and other mediums
US9033976B2 (en) 2000-10-17 2015-05-19 Asthmatx, Inc. Modification of airways by application of energy
US7854734B2 (en) 2000-10-17 2010-12-21 Asthmatx, Inc. Control system and process for application of energy to airway walls and other mediums
US7837679B2 (en) 2000-10-17 2010-11-23 Asthmatx, Inc. Control system and process for application of energy to airway walls and other mediums
US10016592B2 (en) 2001-10-17 2018-07-10 Boston Scientific Scimed, Inc. Control system and process for application of energy to airway walls and other mediums
US8172827B2 (en) 2003-05-13 2012-05-08 Innovative Pulmonary Solutions, Inc. Apparatus for treating asthma using neurotoxin
US10953170B2 (en) 2003-05-13 2021-03-23 Nuvaira, Inc. Apparatus for treating asthma using neurotoxin
US9339618B2 (en) 2003-05-13 2016-05-17 Holaira, Inc. Method and apparatus for controlling narrowing of at least one airway
US8828945B2 (en) 2004-09-18 2014-09-09 Asthmatx, Inc. Inactivation of smooth muscle tissue
US20060062808A1 (en) * 2004-09-18 2006-03-23 Asthmatx, Inc. Inactivation of smooth muscle tissue
US20110184330A1 (en) * 2004-09-18 2011-07-28 Asthmatx, Inc. Inactivation of smooth muscle tissue
US7906124B2 (en) 2004-09-18 2011-03-15 Asthmatx, Inc. Inactivation of smooth muscle tissue
US8731672B2 (en) 2008-02-15 2014-05-20 Holaira, Inc. System and method for bronchial dilation
US8489192B1 (en) 2008-02-15 2013-07-16 Holaira, Inc. System and method for bronchial dilation
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US11058879B2 (en) 2008-02-15 2021-07-13 Nuvaira, Inc. System and method for bronchial dilation
US9125643B2 (en) 2008-02-15 2015-09-08 Holaira, Inc. System and method for bronchial dilation
US8961507B2 (en) 2008-05-09 2015-02-24 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US9668809B2 (en) 2008-05-09 2017-06-06 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8088127B2 (en) 2008-05-09 2012-01-03 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8226638B2 (en) 2008-05-09 2012-07-24 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8808280B2 (en) 2008-05-09 2014-08-19 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US10149714B2 (en) 2008-05-09 2018-12-11 Nuvaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8821489B2 (en) 2008-05-09 2014-09-02 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8961508B2 (en) 2008-05-09 2015-02-24 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8932289B2 (en) 2009-10-27 2015-01-13 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9017324B2 (en) 2009-10-27 2015-04-28 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9675412B2 (en) 2009-10-27 2017-06-13 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9005195B2 (en) 2009-10-27 2015-04-14 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9649153B2 (en) 2009-10-27 2017-05-16 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9931162B2 (en) 2009-10-27 2018-04-03 Nuvaira, Inc. Delivery devices with coolable energy emitting assemblies
US8740895B2 (en) 2009-10-27 2014-06-03 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8777943B2 (en) 2009-10-27 2014-07-15 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9649154B2 (en) 2009-11-11 2017-05-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US11389233B2 (en) 2009-11-11 2022-07-19 Nuvaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US11712283B2 (en) 2009-11-11 2023-08-01 Nuvaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US10610283B2 (en) 2009-11-11 2020-04-07 Nuvaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US10881873B2 (en) 2012-05-31 2021-01-05 Color Seven Co., Ltd Apparatus for relaxing smooth muscles of human body
US9950188B2 (en) 2012-05-31 2018-04-24 Color Seven Co., Ltd. Apparatus for relaxing smooth muscles of human body
US9770293B2 (en) 2012-06-04 2017-09-26 Boston Scientific Scimed, Inc. Systems and methods for treating tissue of a passageway within a body
US9592086B2 (en) 2012-07-24 2017-03-14 Boston Scientific Scimed, Inc. Electrodes for tissue treatment
US10492859B2 (en) 2012-11-05 2019-12-03 Boston Scientific Scimed, Inc. Devices and methods for delivering energy to body lumens
US9974609B2 (en) 2012-11-05 2018-05-22 Boston Scientific Scimed, Inc. Devices and methods for delivering energy to body lumens
US9283374B2 (en) 2012-11-05 2016-03-15 Boston Scientific Scimed, Inc. Devices and methods for delivering energy to body lumens
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation

Also Published As

Publication number Publication date
US20070118190A1 (en) 2007-05-24
CA2370223C (en) 2010-07-20
US8534291B2 (en) 2013-09-17
US7264002B2 (en) 2007-09-04
AU777411B2 (en) 2004-10-14
US20130211402A1 (en) 2013-08-15
US20070062545A1 (en) 2007-03-22
ATE306859T1 (en) 2005-11-15
US7273055B2 (en) 2007-09-25
US20130218158A1 (en) 2013-08-22
DE60023283D1 (en) 2005-11-24
EP1173103A2 (en) 2002-01-23
JP4243436B2 (en) 2009-03-25
JP2002541905A (en) 2002-12-10
AU2004235684A1 (en) 2005-01-06
US8443810B2 (en) 2013-05-21
US20040182399A1 (en) 2004-09-23
EP1173103B1 (en) 2005-10-19
US8733367B2 (en) 2014-05-27
WO2000062699A3 (en) 2001-04-26
DE60023283T2 (en) 2006-07-06
ES2246853T3 (en) 2006-03-01
AU2004235684B2 (en) 2008-06-19
WO2000062699A2 (en) 2000-10-26
US6634363B1 (en) 2003-10-21
AU4800700A (en) 2000-11-02
US7542802B2 (en) 2009-06-02
US20060278244A1 (en) 2006-12-14
CA2370223A1 (en) 2000-10-26
US20040031494A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
US8733367B2 (en) Methods of treating inflammation in airways
US8459268B2 (en) Methods for treating airways
US8464723B2 (en) Methods of evaluating individuals having reversible obstructive pulmonary disease
US10561458B2 (en) Methods for treating airways
US20070106348A1 (en) Method for treating airways in the lung
US20070123958A1 (en) Apparatus for treating airways in the lung
JP6859393B2 (en) Systems, assemblies, and methods for the treatment of bronchial trees
US20170135758A1 (en) Energy delivery and illumination devices and methods

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASTHMATX, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DANEK, CHRISTOPHER JAMES;BIGGS, MICHAEL;LOOMAS, BRYAN;AND OTHERS;REEL/FRAME:019611/0729;SIGNING DATES FROM 20000830 TO 20031226

Owner name: ASTHMATX, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DANEK, CHRISTOPHER JAMES;BIGGS, MICHAEL;LOOMAS, BRYAN;AND OTHERS;SIGNING DATES FROM 20000830 TO 20031226;REEL/FRAME:019611/0729

AS Assignment

Owner name: ASTHMATX, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRONCUS TECHNOLOGIES, INC.;REEL/FRAME:024920/0034

Effective date: 20031226

Owner name: BRONCUS TECHNOLOGIES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DANEK, CHRISTOPHER JAMES;BIGGS, MICHAEL;LOOMAS, BRYAN;AND OTHERS;SIGNING DATES FROM 20000830 TO 20000831;REEL/FRAME:024920/0004

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTHMATX, INC.;REEL/FRAME:040510/0149

Effective date: 20101026

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8